

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	606	(544/330).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L2	1056	(544/331).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L3	1293	(514/275).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L5	21	mark.inv. and Ledeboer.inv. and pyrimidine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:54
L6	7	Brian.inv. and Ledford.inv. and pyrimidine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:54

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	606	(544/330).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L2	1056	(544/331).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L3	1293	(514/275).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:53
L5	21	mark.inv. and Ledeboer.inv. and pyrimidine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:54
L6	7	Brian.inv. and Ledford.inv. and pyrimidine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/06/25 15:54

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1611bxv

**PASSWORD:**

**TERMINAL (ENTER 1, 2, 3, OR ?):2**

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results  
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22 EMBASE is now updated on a daily basis  
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL  
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT  
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected  
NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11 KOREAPAT updates resume  
NEWS 18 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 19 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2  
NEWS 20 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 21 JUN 02 The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/700, 333

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:32:19 ON 25 JUN 2006

=> file req

COST IN U.S. DOLLARS

SINCE FILE TOTAL

**ENTRY**

**TOTAL**

TOM  
ESSTON

**FULL ESTIMATED COST**

0.21

FILE 'REGISTRY' ENTERED AT 15:32:28 ON 25 JUN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5  
DICTIONARY FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

$\Rightarrow$

Uploading C:\Program Files\Stnexp\Queries\107003333.str



chain nodes :

```

Chain Nodes :
 7   16   18   19   20   21   22   23   24   25   26   27   28   29   30   31   32   33   34   35   36
 37   38   39   40   41   42   43   44   45   46   47   48   49   50   51   52   53   54   55   56   57
 58   59   60   61   62

```

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

exact, incl. bonds : 4-7 6-8 7-16 7-18 8-9 8-13 9-10 10-11 11-12 12-13 19-22 19-25 ; 20-23

1-7, 13-15, 18-19, 21-23, 25-27, 30-31, 33-35, 37-39

50-52 50-53 51-56 58-59 59-60 59-61 60-62

normalized bonds :

normalized bonds :

## 1-2 1-8 2-3 3-4 4-5 isolated ring systems :

isolated ring system containing 1 : 8 :

10/700, 333

G1:C,N

G2:[\*1],[\*2],[\*3],[\*4],[\*5],[\*6],[\*7],[\*8],[\*9],[\*10]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 16:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS  
22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS  
30:CLASS 31:Atom 32:CLASS 33:CLASS 34:Atom 35:CLASS 36:CLASS 37:CLASS  
38:CLASS 39:CLASS 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS  
46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS  
54:CLASS 55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS 60:CLASS 61:CLASS  
62:Atom

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam  
SAMPLE SEARCH INITIATED 15:32:57 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 237 TO ITERATE


100.0% PROCESSED 237 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3817 TO 5663  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Urea, N-[4-(2-chlorophenyl)-2-pyrimidinyl]-N'-(3-(trifluoromethyl)phenyl)-(9CI)  
MF C18 H12 Cl F3 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/700, 333


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2 . . .

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI)  
MF C23 H17 N3 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Thiophenecarboxamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]-  
(9CI)  
MF C16 H10 F3 N3 O2 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss sam  
SAMPLE SEARCH INITIATED 15:33:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 237 TO ITERATE

100.0% PROCESSED 237 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 3817 TO 5663  
PROJECTED ANSWERS: 3 TO 163

L3 3 SEA SSS SAM L1

=> s 11 sss ful  
FULL SEARCH INITIATED 15:33:28 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 4932 TO ITERATE

100.0% PROCESSED 4932 ITERATIONS 120 ANSWERS

10/700,333

SEARCH TIME: 00.00.01

L4 120 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
167.38 167.59

FILE 'CAPLUS' ENTERED AT 15:33:36 ON 25 JUN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Jun 2006 VOL 145 ISS 1  
FILE LAST UPDATED: 23 Jun 2006 (20060623/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14  
L5 25 L4

=> d 15 1-25 bib hitstr

L5 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1260610 CAPLUS  
DN 144:22946  
TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases  
IN Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.  
PA Amgen Inc., USA  
SO PCT Int. Appl., 540 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113494	A2	20051201	WO 2005-US16346	20050509
	WO 2005113494	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG

US 2006009453      A1      20060112      US 2005-126000      20050509  
 PRAI US 2004-569193P      P      20040507

OS MARPAT 144:22946


IT 870232-85-2P, N-(4-Chlorophenyl)-N'-[4-[[3-[2-[4-(4-methylpiperazin-1-yl)benzamido]pyrimidin-4-yl]pyridin-2-yl]oxy]phenyl]urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)

RN 870232-85-2 CAPLUS


CN Benzamide, N-[4-[2-[4-[[[(4-chlorophenyl)amino]carbonyl]amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 870221-48-0P, N-[4-(2-Chloropyridin-3-yl)pyrimidin-2-yl]-4-(4-methylpiperazin-1-yl)benzamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)  
 RN 870221-48-0 CAPLUS  
 CN Benzamide, N-[4-(2-chloro-3-pyridinyl)-2-pyrimidinyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:395285 CAPLUS  
 DN 142:430294  
 TI Preparation of pyrimidine compounds as antistress agents  
 IN Ohmoto, Kazuyuki; Kato, Masashi; Katsumata, Seishi; Manako, Junichiro  
 PA Ono Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 133 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040135	A1	20050506	WO 2004-JP16056	20041022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2003-365237 A 20031024  
 OS MARPAT 142:430294  
 IT 850924-15-1P 850924-16-2P 850924-19-5P  
 850924-20-8P 850924-22-0P 850924-23-1P


850924-24-2P 850924-25-3P 850924-28-6P  
850924-29-7P 850924-32-2P 850924-33-3P  
850924-34-4P 850924-35-5P 850924-37-7P  
850924-38-8P 850924-40-2P 850924-41-3P  
850924-42-4P 850924-43-5P 850924-44-6P  
850924-45-7P 850924-46-8P 850924-47-9P  
850924-48-0P 850924-49-1P 850924-50-4P  
850924-51-5P 850924-52-6P 850924-53-7P  
850924-56-0P 850924-57-1P 850924-58-2P  
850924-59-3P 850924-60-6P 850924-61-7P  
850924-68-4P 850924-72-0P 850924-79-7P  
850924-80-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine compds. for treatment of depression, asthma etc.)


RN 850924-15-1 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-16-2 CAPLUS

CN Benzamide, N-[4-(4-methylphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-19-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(trifluoromethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-20-8 CAPLUS


CN Benzamide, N-[4-[3-(trifluoromethyl)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-22-0 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(4-cyanophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-23-1 CAPLUS  
CN Benzamide, N-[4-(4-cyanophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-24-2 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(2-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-25-3 CAPLUS  
CN Benzamide, N-[4-(2-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-28-6 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-29-7 CAPLUS  
CN Benzamide, N-[4-(4-fluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-32-2 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(2,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-33-3 CAPLUS  
CN Benzamide, N-[4-(2,4-difluorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-34-4 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(2-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-35-5 CAPLUS  
CN Benzamide, N-[4-(2-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-37-7 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-38-8 CAPLUS  
CN Benzamide, N-[4-(4-chlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-40-2 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(3-bromophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-41-3 CAPLUS  
CN Benzamide, N-[4-(3-bromophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/700, 333


RN 850924-42-4 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-43-5 CAPLUS  
CN Benzamide, N-[4-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-44-6 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-45-7 CAPLUS  
CN Benzamide, N-[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-46-8 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-47-9 CAPLUS  
CN Benzamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-48-0 CAPLUS  
CN Benzamide, N-[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 850924-49-1 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-(2,5-dimethoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-50-4 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(1-methylethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-51-5 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-52-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(3-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-53-7 CAPLUS

CN Benzamide, N-[4-(3-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-56-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(4-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/700,333


RN 850924-57-1 CAPLUS  
CN Benzamide, N-[4-(4-nitrophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-58-2 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-[3-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-59-3 CAPLUS  
CN Benzamide, N-[4-[3-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-60-6 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-61-7 CAPLUS  
CN Benzamide, N-[4-[4-(acetylamino)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850924-68-4 CAPLUS  
CN 2-Thiophenecarboxamide, N-(4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 850924-72-0 CAPLUS  
CN Benzamide, N-(4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 850924-79-7 CAPLUS  
CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-5-chloro- (9CI) (CA INDEX NAME)



RN 850924-80-0 CAPLUS  
CN Urea, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:324143 CAPLUS  
 DN 142:392430

TI A preparation of pyrimidine derivatives, useful as adenosine receptors ligands

IN Chang, Lisa C. W.; Ijzerman, Adriaan P.; Brussee, Johannes

PA Universiteit Leiden, Neth.

SO PCT Int. Appl., 41 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033085	A1	20050414	WO 2004-NL683	20041001
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2003-23138	A	20031003		
OS	MARPAT	142:392430			
IT	<b>820961-58-8P 820961-72-6P 820961-73-7P 820961-74-8P 820961-75-9P</b>				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
RN	820961-58-8	CAPLUS			
CN	Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)-	(9CI)		(CA INDEX NAME)	




RN 820961-72-6 CAPLUS

CN Cyclopropanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




10/700, 333


RN 820961-73-7 CAPLUS  
CN Cyclobutanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-74-8 CAPLUS  
CN Cyclopentanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-75-9 CAPLUS  
CN Cyclohexanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:973406 CAPLUS  
DN 142:114004  
TI 2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A<sub>1</sub> receptor antagonists  
AU Chang, Lisa C. W.; Spanjersberg, Ronald F.; von Kuenzel, Jacobien K.; Mulder-Krieger, Thea; van den Hout, Gijs; Beukers, Margot W.; Brussee, Johannes; Ijzerman, Adriaan P.  
CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, 2300 RA, Neth.  
SO Journal of Medicinal Chemistry (2004), 47(26), 6529-6540  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English

10/700, 333


OS CASREACT 142:114004  
IT 820961-58-8P 820961-59-9P 820961-60-2P  
820961-61-3P 820961-62-4P 820961-63-5P  
820961-72-6P 820961-73-7P 820961-74-8P  
820961-75-9P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, polar surface area calcns., adenosine A receptor affinity, and structure-activity relationship of N-acyl(diphenyl)pyrimidinamines using heterocyclization and amidation with acid chlorides as the key steps)  
RN 820961-58-8 CAPLUS  
CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-59-9 CAPLUS  
CN Benzamide, 4-chloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-60-2 CAPLUS  
CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 820961-61-3 CAPLUS  
CN Benzamide, N-(4,6-diphenyl-2-pyrimidinyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 820961-62-4 CAPLUS  
CN Benzamide, 3,4-dichloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-63-5 CAPLUS  
CN Benzamide, 3-chloro-N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-72-6 CAPLUS  
CN Cyclopropanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 820961-73-7 CAPLUS  
CN Cyclobutanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-74-8 CAPLUS  
 CN Cyclopentanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 820961-75-9 CAPLUS  
 CN Cyclohexanecarboxamide, N-(4,6-diphenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:878265 CAPLUS  
 DN 141:366255  
 TI Preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors  
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray, Nathanael S.; Schultz, Peter G.  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				


LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
 TD, TG  
 US 2005014753 A1 20050120 US 2004-817328 20040401  
 AU 2004227943 A1 20041021 AU 2004-227943 20040402  
 CA 2521184 AA 20041021 CA 2004-2521184 20040402  
 EP 1613595 A2 20060111 EP 2004-758738 20040402  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 BR 2004009173 A 20060411 BR 2004-9173 20040402  
 PRAI US 2003-460838P P 20030404  
 US 2004-817328 A 20040401  
 WO 2004-US10083 W 20040402  
 OS MARPAT 141:366255  
 IT 778272-89-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of substituted pyrimidinamines and triazinamines as protein  
 kinase inhibitors for treating tumors)  
 RN 778272-89-2 CAPLUS  
 CN Benzamide, 3-chloro-N-[4-[2-[[4-(trifluoromethoxy)phenyl]amino]-4-  
 pyridinyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:292069 CAPLUS  
DN 140:303694  
TI Preparation of substituted pyrimidines for treating disorders mediated by  
the Cannabinoid-1 receptor  
IN Kopka, Ihor E.; Li, Bing; Hagmann, William K.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 181 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029204	A2	20040408	WO 2003-US30161	20030923
WO 2004029204	A3	20040617		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG ..  
 CA 2499497 AA 20040408 CA 2003-2499497 20030923  
 AU 2003275242 A1 20040419 AU 2003-275242 20030923  
 EP 1546115 A2 20050629 EP 2003-759514 20030923  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006510597 T2 20060330 JP 2004-539876 20030923  
 US 2005245554 A1 20051103 US 2005-527561 20050311  
 PRAI US 2002-414144P P 20020927  
 WO 2003-US30161 W 20030923  
 OS MARPAT 140:303694  
 IT **676564-49-1P**, 2-(4-Fluorobenzamido)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine **676564-50-4P**, 2-(Cyclohexylcarbonylamino)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted pyrimidines for treating disorders mediated by the cannabinoid-1 receptor)  
 RN 676564-49-1 CAPLUS  
 CN Benzamide, N-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 676564-50-4 CAPLUS  
 CN Cyclohexanecarboxamide, N-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:205964 CAPLUS  
 DN 142:74474  
 TI Product class 12: pyrimidines

AU von Angerer, S.  
 CS Germany  
 SO Science of Synthesis (2004), 16, 379-572  
 CODEN: SSCYJ9  
 PB Georg Thieme Verlag  
 DT Journal; General Review  
 LA English  
 IT 54286-80-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrimidines via cyclization, ring transformation,  
 aromatization and substituent modification)  
 RN 54286-80-5 CAPLUS  
 CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX  
 NAME)



RE.CNT 856 THERE ARE 856 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:551510 CAPLUS  
 DN 139:117434  
 TI Aminopyrimidines as adenosine receptor antagonists, processes for their  
 preparation and pharmaceutical compositions  
 IN Tsutsumi, Hideo; Yonishi, Satoshi; Akahane, Atsushi  
 PA Fujisawa Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 220 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2003057689	A1	20030717	WO 2002-JP13796	20021227	
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002358999	A1	20030724	AU 2002-358999	20021227
	US 2005043315	A1	20050224	US 2004-498016	20040616
PRAI	AU 2002-9796	A	20020102		
	AU 2002-1724	A	20020412		
	AU 2002-951403	A	20020916		
	WO 2002-JP13796	W	20021227		
IT	560113-60-2P, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-				

phenyl-2-pyrimidinyl]cyclohexanecarboxamide **560113-62-4P**,  
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]cyclopropanecarboxamide **560113-64-6P**,  
 N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-65-7P**, 4-Fluoro-N-[5-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-66-8P**, 4-Chloro-N-[5-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]benzamide **560113-67-9P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-methoxybenzamide **560113-68-0P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-methylbenzamide **560113-69-1P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]-4-(trifluoromethyl)benzamide **560113-70-4P**, N-[5-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenyl-2-pyrimidinyl]nicotinamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (A1 and A2a adenosine receptor ligand; preparation of aminopyrimidines as adenosine receptor antagonists)


RN 560113-60-2 CAPLUS

CN Cyclohexanecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 560113-62-4 CAPLUS

CN Cyclopropanecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 560113-64-6 CAPLUS

CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 560113-65-7 CAPLUS

CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 560113-66-8 CAPLUS

CN Benzamide, 4-chloro-N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 560113-67-9 CAPLUS

CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 560113-68-0 CAPLUS


CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 560113-69-1 CAPLUS  
 CN Benzamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 560113-70-4 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[5-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-4-phenyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:658746 CAPLUS  
 DN 137:185833  
 TI Preparation of novel heterocyclic urea compounds, particularly N-hydroxy-2-[N-substituted-N-[(2-substituted-pyrrolidin-1-yl)carbonyl]amino]acetamides, with activity as peptide deformylase inhibitors, their compositions and methods of use as antimicrobials  
 IN Jacobs, Jeffrey W.; Patel, Dinesh; Lewis, Jason; Ni, Zhi-Jie  
 PA Vicuron Pharmaceuticals Inc., USA  
 SO U.S. Pat. Appl. Publ., 40 pp.  
 CODEN: USXXCO

DT Patent  
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002119962	A1	20020829	US 2000-738376	20001213
	US 6852752	B2	20050208		
PRAI	US 1999-266329P	P	19991217		

10/700, 333

OS MARPAT 137:185833

IT 345890-40-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heterocyclic urea hydroxamates as peptide deformylase inhibitors for use as antimicrobials)

RN 345890-40-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:639736 CAPLUS

DN 138:201537

TI N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity

AU Hackbarth, Corinne J.; Chen, Dawn Z.; Lewis, Jason G.; Clark, Kirk; Mangold, James B.; Cramer, Jeffrey A.; Margolis, Peter S.; Wang, Wen; Koehn, Jim; Wu, Charlotte; Lopez, S.; Withers, George, III; Gu, Helen; Dunn, Elina; Kulathila, R.; Pan, Shi-Hao; Porter, Wilma L.; Jacobs, Jeff; Trias, Joaquim; Patel, Dinesh V.; Weidmann, Beat; White, Richard J.; Yuan, Zhengyu

CS Versicor, Inc., Fremont, CA, 94555, USA

SO Antimicrobial Agents and Chemotherapy (2002), 46(9), 2752-2764  
CODEN: AMACQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

IT 345890-40-6P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(alkyl urea hydroxamic acids as new class of peptide deformylase inhibitors with antibacterial activity)

RN 345890-40-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:453006 CAPLUS

DN 135:61229

TI Novel heterocyclic urea compounds, particularly N-hydroxy-2-[N-substituted-N-[(2-substituted-pyrrolidin-1-yl)carbonyl]amino]acetamides, with activity as peptide deformylase inhibitors, and their compositions, methods of use as antimicrobials, and preparation

IN Ni, Zhi-jie; Jacobs, Jeffrey W.; Patel, Dinesh V.; Lewis, Jason

PA Versicor, Inc., USA

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044178	A1	20010621	WO 2000-US34126	20001213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-266329P	P	19991217		
	US 1999-466402	A1	19991217		
OS	MARPAT	135:61229			
IT	345890-40-6P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of heterocyclic urea hydroxamates as peptide deformylase inhibitors for use as antimicrobials)				
RN	345890-40-6	CAPLUS			
CN	1,2-Pyrrolidinedicarboxamide, N1-(2-cyclopentylethyl)-N1-[2-(hydroxyamino)-2-oxoethyl]-N2-(4-phenyl-2-pyrimidinyl)-, (2S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:78219 CAPLUS  
 DN 134:141718  
 TI Pyrimidine derivative inhibitors of viral helicase  
 IN Hale, Michael; Maltais, Francois; Baker, Christopher; Janetka, James;  
 Moon, Young Choon; Saunders, Jeffrey  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2001007027	A2	20010201	WO 2000-US19650	20000719
WO 2001007027	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 1999-145193P	P	19990722		
US 1999-150783P	P	19990826		
OS MARPAT 134:141718				
IT 322390-82-9				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrimidine derivative inhibitors of viral helicase)				
RN 322390-82-9 CAPLUS				
CN Urea, N-[6-(4-bromophenyl)-5-cyano-1,4-dihydro-4-oxo-2-pyrimidinyl]-N'-(3-fluorophenyl)-(9CI) (CA INDEX NAME)				




L5 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:227649 CAPLUS  
 DN 132:265206  
 TI Preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease  
 IN Watanabe, Kazutoshi; Ando, Ryoichi; Saito, Ken-ichi; Kawamoto, Rie; Shoda, Aya  
 PA Mitsubishi Chemical Corporation, Japan  
 SO PCT Int. Appl., 106 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018758	A1	20000406	WO 1999-JP5224	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	CA 2345065	AA	20000406	CA 1999-2345065	19990924
	AU 9957599	A1	20000417	AU 1999-57599	19990924
	EP 1115721	A1	20010718	EP 1999-944815	19990924
	EP 1115721	B1	20031210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525366	T2	20020813	JP 2000-572218	19990924
	AT 256123	E	20031215	AT 1999-944815	19990924
	PT 1115721	T	20040430	PT 1999-944815	19990924
	ES 2214045	T3	20040901	ES 1999-944815	19990924
PRAI	JP 1998-271277	A	19980925		
	JP 1998-305266	A	19981027		
	WO 1999-JP5224	W	19990924		
OS	MARPAT	132:265206			
IT	<b>263244-10-6P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease)				
RN	263244-10-6	CAPLUS			
CN	Benzamide, N-[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)				




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1998:446847 CAPLUS  
 DN 129:135874  
 TI Strong Dimerization of Ureidopyrimidones via Quadruple Hydrogen Bonding  
 AU Beijer, Felix H.; Sijbesma, Rint P.; Kooijman, Huub; Spek, Anthony L.;  
 Meijer, E. W.  
 CS Laboratory of Organic Chemistry, Eindhoven University of Technology,  
 Eindhoven, 5600 MB, Neth.  
 SO Journal of the American Chemical Society (1998), 120(27), 6761-6769  
 CODEN: JACSAT; ISSN: 0002-7863  
 PB American Chemical Society  
 DT Journal  
 LA English  
 IT 210709-60-7P 210709-61-8P 210709-62-9P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (hydrogen bond dimer formation for ureidopyrimidones via quadruple  
 hydrogen bonding)  
 RN 210709-60-7 CAPLUS  
 CN Urea, N-[1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl]-  
 N'-phenyl- (9CI) (CA INDEX NAME)




RN 210709-61-8 CAPLUS  
 CN Urea, N-[1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl]-  
 N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 210709-62-9 CAPLUS

CN Urea, N-[4-(diethylamino)phenyl]-N'-(1,4-dihydro-4-oxo-6-[3,4,5-tris(dodecyloxy)phenyl]-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:394334 CAPLUS

DN 129:67791

TI Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs

IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824782	A2	19980611	WO 1997-US22390	19971204
	WO 9824782	A3	19980827		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	CA 2274063	AA	19980611	CA 1997-2274063	19971204
	AU 9860120	A1	19980629	AU 1998-60120	19971204
	AU 733877	B2	20010531		
	EP 948497	A2	19991013	EP 1997-954778	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9713850	A	20000229	BR 1997-13850	19971204
	CN 1246858	A	20000308	CN 1997-181563	19971204
	NZ 335997	A	20010831	NZ 1997-335997	19971204


JP 2002514195	T2	20020514	JP 1998-525850	19971204
TW 520362	B	20030211	TW 1997-86118244	19971204
EP 1314731	A2	20030528	EP 2002-27704	19971204
EP 1314731	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
EP 1314732	A2	20030528	EP 2002-27705	19971204
EP 1314732	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
ZA 9710911	A	19980605	ZA 1997-10911	19971205
MX 9905168	A	20000228	MX 1999-5168	19990603
US 6410729	B1	20020625	US 2000-598740	20000621
US 2003069425	A1	20030410	US 2002-117552	20020403
US 6610698	B2	20030826		
PRAI US 1996-32128P	P	19961205		
US 1997-50950P	P	19970613		
US 1997-976054	A	19971121		
EP 1997-954778	A3	19971204		
US 1997-984774	B1	19971204		
WO 1997-US22390	W	19971204		
US 2000-598740	A3	20000621		
OS MARPAT 129:67791				
IT 208936-03-2P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)				
RN 208936-03-2 CAPLUS				
CN Benzamide, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)				



L5	ANSWER 16 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN
AN	1995:611675 CAPLUS
DN	123:285884
TI	Synthesis and reactions of 2-amino-4-aryl-6-(2'-methoxynaphthyl)pyrimidines
AU	Essawy, S. A.; El-Sawy, A. A.; Issac, Y. A.; Ghany, A. M. Abdel
CS	Faculty Science, Benha University, Benha, Egypt
SO	Egyptian Journal of Chemistry (1994), 37(4), 423-31
	CODEN: EGJCA3; ISSN: 0367-0422
PB	National Information and Documentation Centre
DT	Journal
LA	English
IT	169318-79-0P 169318-82-5P 169318-83-6P 169318-98-3P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and reactions of amino(aryl)(methoxynaphthalenyl)pyrimidines)	


RN 169318-79-0 CAPLUS

CN Urea, N-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 169318-82-5 CAPLUS

CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-methoxy-1-naphthalenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 169318-83-6 CAPLUS

CN Benzamide, N-[4-(2-methoxy-1-naphthalenyl)-6-(4-methoxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 169318-98-3 CAPLUS


CN Urea, N-[4-(2-methoxy-1-naphthalenyl)-6-(4-methoxyphenyl)-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1994:435528 CAPLUS  
 DN 121:35528  
 TI Synthesis and biological activity of some 4-(p-chlorophenyl)-6-(o-hydroxyphenyl)-2-aminopyrimidine derivatives: Part 1  
 AU Abdel-Halim, A. M.; Tawfik, A. M.; Ibrahim, S. S.; El-Kazak, A. M.  
 CS Fac. Educ., Ain Shams Univ., Cairo, Egypt  
 SO Indian Journal of Heterocyclic Chemistry (1994), 3(3), 165-70  
 CODEN: IJCHEI; ISSN: 0971-1627  
 DT Journal  
 LA English  
 IT 155733-31-6P 155733-32-7P 155733-33-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 155733-31-6 CAPLUS  
 CN Benzamide, 4-chloro-N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 155733-32-7 CAPLUS  
 CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 155733-33-8 CAPLUS

10/700, 333

CN Benzamide, N-[4-(4-chlorophenyl)-6-(2-hydroxyphenyl)-2-pyrimidinyl]-4-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:38868 CAPLUS

DN 118:38868

TI A facile one-step conversion of  $\beta$ -benzoylacrylic acids into some interesting heterocycles and study of their microbiological activity

AU El-Kafrawy, A. F.; El-Bassiouny, F. A.; Sayed, M. A.; El-Hashash, M. A.

CS Fac. Sci., Ain Shams Univ., Cairo, Egypt

SO Journal of the Chemical Society of Pakistan (1992), 14(1), 59-66

CODEN: JCSPDF; ISSN: 0253-5106

DT Journal

LA English


OS CASREACT 118:38868

IT 145274-36-8P 145274-37-9P 145274-38-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 145274-36-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(benzoylamino)-6-(4-phenoxyphenyl)- (9CI)  
(CA INDEX NAME)




RN 145274-37-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-(benzoylamino)-6-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




10/700, 333


RN 145274-38-0 CAPLUS  
CN 4-Pyrimidinecarboxylic acid, 2-[(2-chlorobenzoyl)amino]-6-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1987:407157 CAPLUS  
DN 107:7157  
TI Heterocyclic rearrangements. Synthesis of 1,2,4-oxadiazolo[2,3-a]pyrimidinium systems and their ring opening into pyrimidine N-oxides  
AU Buscemi, Silvestre; Macaluso, Gabriella; Frenna, Vincenzo; Vivona, Nicolo  
CS Ist. Chim. Org., Univ. Palermo, Palermo, 90123, Italy  
SO Journal of Heterocyclic Chemistry (1986), 23(4), 1175-7  
CODEN: JHTCAD; ISSN: 0022-152X  
DT Journal  
LA English  
OS CASREACT 107:7157  
IT 108656-01-5P 108656-08-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrolysis of)  
RN 108656-01-5 CAPLUS  
CN Benzamide, N-(4-methyl-1-oxido-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 108656-08-2 CAPLUS  
CN Benzamide, N-(6-methyl-1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1982:85504 CAPLUS  
 DN 96:85504  
 TI Alkylation and acylation of 2-aminopyrimidine N-oxides  
 AU Sedova, V. F.; Mustafina, T. Yu.; Mamaev, V. P.  
 CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR  
 SO Khimiya Geterotsiklichesikh Soedinenii (1981), (11), 1515-22  
 CODEN: KGSSAQ; ISSN: 0453-8234  
 DT Journal  
 LA Russian  
 OS CASREACT 96:85504  
 IT **80830-47-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of, with perchloric acid)  
 RN 80830-47-3 CAPLUS  
 CN Benzamide, N-(1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT **80830-59-7P 80830-65-5P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 80830-59-7 CAPLUS  
 CN Urea, N-(1-oxido-4-phenyl-2-pyrimidinyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 80830-65-5 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-(1-oxido-4-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN.  
 AN 1981:30763 CAPLUS  
 DN 94:30763  
 TI Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and -1H-1,2,4-triazoles  
 IN Heeres, Jan; Mostmans, Joseph H.  
 PA Janssen Pharmaceutica N. V., Belg.  
 SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 918,257, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4218458	A	19800819	US 1979-20287	19790314
EP 6712	A1	19800109	EP 1979-301130	19790613
EP 6712	B1	19831130		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 5479	E	19831215	AT 1979-301130	19790613
JP 55011579	A2	19800126	JP 1979-77630	19790621
JP 63044752	B4	19880906		
US 4313953	A	19820202	US 1980-134384	19800327
US 4533550	A	19850806	US 1981-558331	19810827
PRAI US 1978-918257	A2	19780623		
US 1979-20287		19790314		
EP 1979-301130	A	19790613		
US 1980-134384	A3	19800327		
OS CASREACT 94:30763; MARPAT 94:30763				
IT 74740-41-3P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of fungicidal and bactericidal)				
RN 74740-41-3, CAPLUS				
CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-4-fluoro-, cis- (9CI) (CA INDEX NAME)				

Relative stereochemistry.



10/700, 333


IT **74740-40-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, fungicidal and bactericidal)

RN 74740-40-2 CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:514502 CAPLUS

DN 93:114502

TI Pesticidal heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and -1H-1,2,4-triazoles

IN Heeres, Jan; Mostmans, Joseph

PA Janssen Pharmaceutica N. V., Belg.

SO Eur. Pat. Appl., 89 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 6712	A1	19800109	EP 1979-301130	19790613
	EP 6712	B1	19831130		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE US 4218458 AT 5479	A	19800819	US 1979-20287	19790314
		E	19831215	AT 1979-301130	19790613
PRAI	US 1978-918257		19780623		
	US 1979-20287		19790314		
	EP 1979-301130	A	19790613		
IT	<b>74740-40-2P</b> <b>74740-41-3P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	74740-40-2 CAPLUS				
CN	Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-, cis- (9CI) (CA INDEX NAME)				


Relative stereochemistry.



RN 74740-41-3 CAPLUS

CN Benzamide, N-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-2-pyrimidinyl]-4-fluoro-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



LS ANSWER 23 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:155600 CAPLUS

DN 86:155600

TI Synthesis of a new ring system: 1,2,4-oxidiazole[2,3a]pyrimidin-4-one

AU Vivona, Nicolo; Cusmano, Giuseppe

CS Fac. Sci., Univ. Palermo, Palermo, Italy

SO Heterocycles (1977), 6(2), 107-10

CODEN: HTCYAM; ISSN: 0385-5414

DT Journal


LA English

10/700,333

OS CASREACT 86:155600

IT 54286-80-5P

RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, in hydrogenation of diphenyloxadiazolopyrimidinone)  
RN 54286-80-5 CAPLUS  
CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:43328 CAPLUS

DN 82:43328

TI Heterocyclic transformations by hydrogenolysis. Pyrimidine derivatives from 1,2,4-oxadiazole derivatives

AU Ruccia, M.; Vivona, N.; Cusmano, G.

CS Ist. Chim. Org., Fac. Sci., Palermo, Italy

SO Journal of Heterocyclic Chemistry (1974), 11(5), 829-30

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal


LA English

IT 54286-80-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 54286-80-5 CAPLUS

CN Benzamide, N-(1,4-dihydro-4-oxo-6-phenyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1955:23952 CAPLUS

DN 49:23952

OREF 49:4658f-i,4659a-c

TI Guanidine and biguanidine derivatives. II. Synthesis of new derivatives of o-phenylenebiguanide, 2-aminobenzimidazole,  $\omega$ -phenylbiguanide, guanilphenylurea, and guanilurea

AU Ridi, Mario; Checchi, Silvio


CS Univ. Florence

SO Annali di Chimica (Rome, Italy) (1954), 44, 28-38

CODEN: ANCRAI; ISSN: 0003-4592



10/700, 333

DT Journal  
LA Unavailable  
IT 859734-98-8, Urea, 1-(3,4-dihydro-4-oxo-6-phenyl-2-(1H)-pyrimidinylidene)-3-phenyl-(preparation of)  
RN 859734-98-8 CAPLUS  
CN Urea, 1-(3,4-dihydro-4-oxo-6-phenyl-2-(1H)-pyrimidinylidene)-3-phenyl-(5CI) (CA INDEX NAME)



STN INTERNATIONAL LOGOFF AT 15:34:09 ON 25 JUN 2006

10/700,333





chain nodes :  
7 14 17 18  
ring nodes :  
1 2 3 4 5 6 8 9 10 11 12 13  
chain bonds :  
1-17 3-7 5-10 14-18  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13  
exact/norm bonds :  
3-7 14-18  
exact bonds :  
1-17 5-10  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13  
isolated ring systems :  
containing 1 : 8 :  
  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS

6.25-06

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10639784.str



chain nodes :

7 14

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

3-7 5-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

3-7

exact bonds :

5-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11 sss sam
SAMPLE SEARCH INITIATED 19:41:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      1319 TO ITERATE



100.0% PROCESSED      1319 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS:  ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS:   24202 TO 28558
PROJECTED ANSWERS:      5859 TO 8099
```

L2 50 SEA SSS SAM L1

```
=> =>
Uploading C:\Program Files\Stnexp\Queries\10639784 (a).str
```



```
chain nodes :
7 14 17
```

```


ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-17 3-7 5-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
3-7
exact bonds :
1-17 5-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
isolated ring systems :
containing 1 : 8 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS

```

L3       STRUCTURE UPLOADED

=> d 13  
L3 HAS NO ANSWERS  
L3           STR



Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam  
SAMPLE SEARCH INITIATED 19:43:35 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -     1319 TO ITERATE

100.0% PROCESSED     1319 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


50 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 24202 TO 28558  
 PROJECTED ANSWERS: 2671 TO 4249

L4 50 SEA SSS SAM L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10639784 (b).str



chain nodes :

7 14 17 18

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13

chain bonds :

1-17 3-7 5-10 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

exact/norm bonds :

3-7 14-18

exact bonds :

1-17 5-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13

isolated ring systems :

containing 1 : 8 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 17:CLASS 18:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 15 sss sam
SAMPLE SEARCH INITIATED 19:44:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      1319 TO ITERATE

100.0% PROCESSED      1319 ITERATIONS          27 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS:    24202 TO   28558
PROJECTED ANSWERS:       229 TO     851

L6      27 SEA SSS SAM L5

=> => s 15 sss ful
FULL SEARCH INITIATED 19:45:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      26604 TO ITERATE

100.0% PROCESSED      26604 ITERATIONS          446 ANSWERS
SEARCH TIME: 00.00.01

L7      446 SEA SSS FUL L5

=> => s 17
L8      29 L7

=> d 18 1-29 bib,ab,hitstr
```

L8 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:1075803 CAPLUS  
 DN 143:367317  
 TI Preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase  
 IN Delorme, Daniel; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana;  
 Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliiane; Zhou, Zhihong;  
 Paquin, Isabelle; Gaudette, Frederic; Isakovic, Ljubomir  
 PA Methylgene Inc., Can.  
 SO PCT Int. Appl., 245 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005092899	A1	20051006	WO 2005-CA454	20050329
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, GF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI US 2004-556828P	P	20040326		
US 2005-90713	A	20050325		
WO 2005-IB802	A	20050325		
AB	The invention relates to N-(2-amino and 2-hydroxy)phenyl carboxamides (2-TC6H4NHC(O)(CH:CH)qAr-X-Cy (I); variables defined below; e.g. (E)-N-(2-Aminophenyl)-3-[4-[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide (shown as II)) useful for inhibiting histone deacetylase (HDAC) enzymic activity. The invention also provides a method for inhibiting histone deacetylase in a cell using said compds. as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compns. comprising the HDAC inhibiting compds. and a pharmaceutically acceptable carrier. For I: Cy is aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is (un)substituted and each of which is optionally fused to $\geq 1$ aryl or heteroaryl rings, or to $\geq 1$ saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings is (un)substituted; X = a chemical bond, L, W-L, L-W, and L-W-L, wherein W, at each occurrence, is S, O, C=O, or N(R9), where R9 = H, alkyl, hydroxyalkyl, and tert-butoxycarbonyl; and L = C1-C4 alkylene; Ar is arylene or heteroarylene, each of which is (un)substituted; q = 0-1; and T is NH2 or OH, provided that when Cy is naphthyl, X is -CH2-, Ar is Ph, and q = 0-1, T is not OH. Although the methods of preparation are not claimed, 215 example preps. and/or characterization data are included. For example, II was prepared in 6 steps (59, 83, 97, 79, 96 and 80 % yields) starting from (E)-4-formylcinnamic acid and involving intermediates Me (E)-3-(4-formylphenyl)acrylate, Me (E)-3-[4-[(2-(1H-indol-3-yl)ethyl)amino]methyl]phenyl]acrylate, Me (E)-3-[4-[(2-[(tert-butyldimethylsilyl)oxy]ethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, (E)-3-[4-[(2-[(tert-butyldimethylsilyl)oxy]ethyl)[2-(1H-indol-3-			

yl)ethyl]amino)methyl]phenyl]acrylic acid and (E)-N-(2-aminophenyl)-3-[4-[[[2-[(tert-butyldimethylsilyl)oxy]ethyl]2-(1H-indol-3-yl)ethyl]amino)methyl]phenyl]acrylamide.


IT 866000-03-5P, 4-[[[4-(3-Acetylphenyl)pyrimidin-2-yl]amino)methyl]-N-(2-aminophenyl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase)

RN 866000-03-5 CAPIUS

CN Benzamide, 4-[[[4-(3-acetylphenyl)-2-pyrimidinyl]amino)methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:823509 CAPLUS  
 DN 143:229572  
 TI Preparation of benzamides for treating a disorder mediated by inappropriate ROCK-1 activity  
 IN Drewry, David Kendall; Jung, David Kendall; Linn, James Andrew; Hunter, Robert Neil, III; Lee, Dennis; Stavenger, Robert A.; Sehon, Clark  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005074643	A2	20050818	WO 2005-US3479	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-540621P P 20040130

OS MARPAT 143:229572

AB The title compds. I [R1 = H, alkyl or as indicated by the dotted line is fused to the Ph forming a 5-6 membered ring, optionally containing a double bond; n = 0-4; R2 = (un)substituted aryl, etc.; or when n = 0 then NR1R2 = 5-6 membered monocyclic heterocyclic ring or 9-10 membered bicyclic heterocyclic ring; X = indazolyl, pyrazolyl, (un)substituted pyridyl, pyrimidinyl], useful for treating disorders mediated by inappropriate ROCK-1 activity, were prepared E.g., a 3-step synthesis of II, starting from Me 4-bromobenzoate and 4-pyridylboronic acid, was given. All exemplified compds. I showed inhibitory activity vs. Rock-1 with a pIC50 of 5.0 or greater. The pharmaceutical composition comprising the compound I is disclosed.


IT 862723-00-0P 862723-07-7P 862723-08-8P  
 862723-09-9P 862723-10-2P 862723-11-3P  
 862723-12-4P 862723-13-5P 862723-14-6P  
 862723-15-7P 862723-16-8P 862723-17-9P  
 862723-18-0P 862723-19-1P 862723-20-4P  
 862723-21-5P 862723-22-6P 862723-23-7P  
 862723-24-8P 862723-26-0P 862723-27-1P  
 862723-28-2P 862723-30-6P 862723-32-8P  
 862723-33-9P 862723-34-0P 862723-35-1P  
 862723-36-2P 862723-38-4P 862723-39-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzamides for treating a disorder mediated by inappropriate ROCK-1 activity)

RN 862723-00-0 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-methoxyphenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-07-7 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(4-methoxyphenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-08-8 CAPIUS  
 CN Benzamide, 4-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-09-9 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-10-2 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-11-3 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-12-4 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-13-5 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(2-methoxyphenyl)methyl]- (9CI)  
 (CA INDEX NAME)



RN 862723-14-6 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]- (9CI)  
 (CA INDEX NAME)




RN 862723-15-7 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)- (9CI)  
 (CA INDEX NAME)




RN 862723-16-8 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 862723-17-9 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-18-0 CAPLUS  
 CN Carbamic acid, [[3-[[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 862723-19-1 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[{(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-20-4 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[{(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 862723-21-5 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[{(3-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 862723-22-6 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 862723-23-7 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-(4-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 862723-24-8 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]-(9CI) (CA INDEX NAME)


**Absolute stereochemistry.**




RN 862723-26-0 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]-(9CI) (CA INDEX NAME)




RN 862723-27-1 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3-(difluoromethoxy)phenyl)methyl]-(9CI) (CA INDEX NAME)




RN 862723-28-2 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)-(9CI) (CA INDEX NAME)



RN 862723-30-6 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]-(9CI) (CA INDEX NAME)




RN 862723-32-8 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1,1'-biphenyl)-4-ylmethyl]-(9CI) (CA INDEX NAME)




RN 862723-33-9 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-34-0 CAPIUS  
 CN Carbamic acid, [3-[1-[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]ethyl]phenyl], 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 862723-35-1 CAPIUS  
 CN Benzamide, N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 862723-36-2 CAPIUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-38-4 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 862723-39-5 CAPLUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 216959-98-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of benzamides for treating a disorder mediated by inappropriate  
ROCK-1 activity)


RN 216959-98-7 CAPIUS

CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 3 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:638854 CAPLUS  
 DN 143:153392  
 TI Preparation of aryl pyrimidines as protein kinase C inhibitors  
 IN Fleming, Paul E.; Shi, Zhan; Chen, Shaowu; Schmidt, Jane F.; Reader, John C.; Hone, Neal D.; Ciavarri, Jeffrey P.  
 PA Millennium Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 177 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200506139	A2	20050721	WO 2005-US663	20050110
	A3	20051013		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2004-534898P	P	20040108		
OS MARPAT 143:153392				
AB Title compds. I [R1 and R2 independently = H, alkyl, cycloalkyl; R3 = H or F; R4 = H, F, C(O)R, etc., or R3 and R4 together = carbonyl; R = H, alkyl, cycloalkyl; ring A is optionally substituted with R5; R5 = halo, CN, aliphatic, etc.; Cyl = (un)substituted 6-membered aryl or heteroaryl, 5-membered heteroaryl; Q = bond, CH <sub>2</sub> , CO; Cy2 = (un)substituted aryl, heteroaryl, heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase C (PKC) inhibitors. Thus, e.g., II was prepared by coupling of (3-[(3-(2-chloro-pyrimidin-4-yl)-benzyl]-ethyl-amino)-propyl)carbamic acid tert-Bu ester (preparation given) with tyramine and subsequent deprotection. The inhibitory activity of I against PKC-theta isoform was evaluated in an enzyme assay following the emission of europium cryptate (at 615 nm) and streptavidin-allophycocyanin (at 665 nm) and it was revealed that selected compds. of the invention display IC <sub>50</sub> values less than 100 nM. I as PKC inhibitor should prove useful in the treatment of inflammatory diseases such as, but not limited to, rheumatoid arthritis, asthma, and multiple sclerosis. Pharmaceutical compns. comprising I are disclosed.				
IT 859514-46-8P				
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of aryl pyrimidines as protein kinase C inhibitors)				
RN 859514-46-8 CAPLUS				
CN Benzoic acid, 3-[2-[(2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)				



IT 859514-47-9P 859514-48-0P 859514-49-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aryl pyrimidines as protein kinase C inhibitors)  
 RN 859514-47-9 CAPLUS  
 CN Benzamide, 3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]-N-(3-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-48-0 CAPLUS  
 CN Benzamide, N-(3-aminopropyl)-3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 859514-49-1 CAPIUS

CN Benzamide, 3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]-N-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 859516-87-3P 859517-06-9P 859517-17-2P,


1-(3-[2-[(2-(4-Methoxyphenyl)ethyl)amino]pyrimidin-4-yl]phenyl)ethanone  
859517-31-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of aryl pyrimidines as protein kinase C inhibitors)

RN 859516-87-3 CAPIUS


CN Benzoic acid, 3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 859517-06-9 CAPIUS  
 CN Benzaldehyde, 3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)



RN 859517-17-2 CAPIUS  
 CN Ethanone, 1-[3-[2-[(2-(4-methoxyphenyl)ethyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859517-31-0 CAPIUS  
 CN Ethanone, 1-[3-[2-[(2-(4-hydroxyphenyl)ethyl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:878265 CAPLUS  
 DN 141:366255  
 TI Preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors  
 IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray, Nathanael S.; Schultz, Peter G.  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005014753	A1	20050120	US 2004-817328	20040401
	CA 2521184	AA	20041021	CA 2004-2521184	20040402
PRAI	US 2003-460838P	P	20030404		
	US 2004-817328	A	20040401		
	WO 2004-US10083	W	20040402		
OS	MARPAT 141:366255				
AB	The title compds. [I; X1, X2 = N, CR4 (wherein R4 = H, alkyl); L = a bond, O, NRS (R5 = H, alkyl); R1 = X3NR6R7, X3OR7, X3R7 (X3 = a bond, alkylene; R6 = H, alkyl; R7 = aryl, heteroaryl); R2 = H, halo, NH2, etc.; R3 = (heterocycloalkyl)alkyl, heteroarylalkyl, arylalkyl, etc.], useful for treating or preventing diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl, were prepared E.g., a multi-step synthesis of II, starting from 4,6-dichloropyrimidine and p-trifluoromethoxyaniline, was given. The compds. I preferably show an IC50 in the range of 1x10-10 to 1x10-5M for Bcr-abl (specific data for one of the exemplified compds. I are given). The pharmaceutical composition comprising the compound I is claimed.				
IT	778275-99-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)				
RN	778275-99-3 CAPLUS				
CN	Benzamide, 3-[2-[(4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				



L8 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:780678 CAPLUS  
 DN 141:277637  
 TI Preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives for inhibition of angiogenesis  
 IN Lee, Jinho; Kim, Hak Joong; Choi, Seihyun; Choi, Hwan Geun; Yoon, Seunghyun; Kim, Jong-Hyun; Jo, Kiwon; Kim, Semi; Koo, Sun-Young; Kim, Min-Hyeung; Kim, Jung In; Hong, Sang-Yong; Kim, Mi Sun; Ahn, Shinbyoung; Yoon, Hae-Seong; Cho, Heung-Soo  
 PA LG Life Sciences Ltd., S. Korea  
 SO PCT Int. Appl., 110 pp.  
 CODEN: PIIXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080979	A1	20040923	WO 2004-KR301	20040213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-454335P P 20030314

OS MARPAT 141:277637

AB Title compds. I [R1 = (hetero)aromatic ring; R2 = H, alkyl, aryl, etc.; R3 = H, alkyl, X1n1NX2X3, etc.; X1 = H, alkylene, etc.; X2 = H, alkoxy, pyrrolidine, etc.; n1 = 0-1; X3 = H, alkyl, (hetero)aryl, etc.] are prepared. For instance, [3-(2-aminopyrimidin-4-yl)-4-hydroxyphenyl]phenylmethanone (II) is prepared from 3-(2-aminopyrimidin-4-yl)-4-benzoyloxy-N-methoxy-N-methylbenzamide (preparation given) and bromobenzene (THF, n-BuLi, -78°) in 47.5% yield. II has IC50 > 0.1 μM for KDR kinase. I are angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ('KDR'); they are useful for the treatment and prevention of angiogenesis-related diseases, particularly resulting from the unregulated or undesired KDR activity, such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy.

IT 761000-95-7P 761000-96-8P 761000-97-9P  
 761001-02-9P 761001-03-0P 761001-04-1P  
 761001-05-2P 761001-06-3P 761001-07-4P  
 761001-08-5P 761001-09-6P 761001-10-9P  
 761001-11-0P 761001-12-1P 761001-13-2P  
 761001-14-3P 761001-15-4P 761001-16-5P  
 761001-17-6P 761001-18-7P 761001-19-8P  
 761001-37-0P 761001-38-1P 761001-39-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs. for inhibition of angiogenesis)


RN 761000-95-7 CAPLUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]phenyl- (9CI) (CA INDEX NAME)




RN 761000-96-8 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](2-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 761000-97-9 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](2,6-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 761001-02-9 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 761001-03-0 CAPIUS


CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 761001-04-1 CAPIUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](2-fluorophenyl)-  
 (9CI) (CA INDEX NAME)




RN 761001-05-2 CAPIUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][1,1'-biphenyl]-4-yl-  
 (9CI) (CA INDEX NAME)




RN 761001-06-3 CAPIUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][1,1'-biphenyl]-3-yl-  
 (9CI) (CA INDEX NAME)




RN 761001-07-4 CAPIUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](3-bromo-2,4-  
 difluoro-6-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 761001-08-5 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[4-(dimethylamino)-2-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 761001-09-6 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[4-chlorophenyl]- (9CI) (CA INDEX NAME)




RN 761001-10-9 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[2-chloro-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 761001-11-0 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[2-fluoro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-12-1 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[2-methyl-5-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-13-2 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[5-(diethylamino)-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 761001-14-3 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 761001-15-4 CAPLUS  
 CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl]-[4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 761001-16-5 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-17-6 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 761001-18-7 CAPIUS

CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl][3-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-19-8 CAPIUS


CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl](4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 761001-37-0 CAPIUS  
 CN Methanone, (2-fluoro-4-methylphenyl)[4-hydroxy-3-{2-(methylamino)-4-pyrimidinyl}phenyl]- (9CI) (CA INDEX NAME)



RN 761001-38-1 CAPIUS  
 CN Methanone, (4-chloro-2-fluorophenyl)[4-hydroxy-3-{2-(methylamino)-4-pyrimidinyl}phenyl]- (9CI) (CA INDEX NAME)




RN 761001-39-2 CAPIUS  
 CN Glycine, N-[4-[5-(2-fluoro-4-methylbenzoyl)-2-hydroxyphenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 761001-56-3P 761001-57-4P 761001-67-6P  
 761001-68-7P 761001-78-9P 761001-79-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivs. for  
 inhibition of angiogenesis)  
 RN 761001-56-3 CAPIUS


CN Benzoic acid, 3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)-, methyl ester  
(9CI) (CA INDEX NAME)




RN 761001-57-4 CAPIUS  
CN Benzamide, 3-(2-amino-4-pyrimidinyl)-N-methoxy-N-methyl-4-(phenylmethoxy)-  
(9CI) (CA INDEX NAME)



RN 761001-67-6 CAPIUS  
CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)phenyl][3-[(1,1-dimethylethyl)dimethylsilyl]oxy]methylphenyl]- (9CI) (CA INDEX NAME)




RN 761001-68-7 CAPIUS  
CN Methanone, [3-(2-amino-4-pyrimidinyl)-4-(phenylmethoxy)phenyl][3-(chloromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 761001-78-9 CAPLUS

CN Benzamide, N-methoxy-N-methyl-3-[2-(methylamino)-4-pyrimidinyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 761001-79-0 CAPLUS

CN Glycine, N-[4-[5-(2-fluoro-4-methylbenzoyl)-2-(phenylmethoxy)phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:570980 CAPLUS  
 DN 142:134488  
 TI  $\alpha$ -Enones in heterocyclic synthesis, Part I. Classical synthetic and environmentally friendly synthetic approaches to alkyl and acyl azoles and azines  
 AU Al-Shiekh, Mariam A.; El-Din, Abdellatif M. Salah; Hafez, Ebtisam A.; Elnagdi, Mohamed H.  
 CS Department of Chemistry, Girls College of Education, Jeddah, 21 341, Saudi Arabia  
 SO Journal of Chemical Research (2004), (3), 174-179  
 CODEN: JCROA4  
 PB Science Reviews  
 DT Journal  
 LA English  
 OS CASREACT 142:134488  
 AB The utility of  $\alpha$ -oxo enamines RCOCH:CHNMe<sub>2</sub> (R = Et, 4-MeCOC<sub>6</sub>H<sub>4</sub>) in the synthesis of several new azolotriazine, pyrazolo[3,4-d]pyridazine, isoxazolo[3,4-d]pyridazine, azolopyrimidine and pyridine derivs. on conventional heating or under microwave irradiation conditions, is reported.  
 IT 825633-32-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of formazans, dioxo hydrazones, pyridines, pyrazolopyridazines, imidazopyrimidines and other mono- and bicyclic heterocycles from  $\alpha$ -oxo enamines)  
 RN 825633-32-7 CAPLUS  
 CN Ethanone, 1-[4-(2-amino-4-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:451634 CAPLUS  
 DN 141:23544  
 TI Preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition  
 IN Satoh, Yoshitaka; Bhagwat, Shripad S.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 4,645.  
 CODEN: USXXCO  
 DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004106634	A1	20040603	US 2003-395811	20030324
	US 2003220330	A1	20031127	US 2001-4645	20011204
	CA 2520440	AA	20041007	CA 2004-2520440	20040324
	WO 2004084901	A1	20041007	WO 2004-US9208	20040324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-251904P	P	20001206		
	US 2001-4645	A2	20011204		
	US 2003-395811	A	20030324		
	WO 2004-US9208	W	20040324		
OS	MARPAT 141:23544				
AB	The title compds. [I; R1 = (un)substituted (hetero)aryl; R2, R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 10 µM in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition (such as obesity).				
IT	434945-24-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition)				
RN	434945-24-1 CAPLUS				
CN	Benzoic acid, 4-[2-[(4-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				




IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition)

RN 434950-55-7 CAPIUS

CN Benzoic acid, 4-[2-[(4-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:412938 CAPLUS

DN 140:423692

TI Pyridine and pyrimidine derivatives and their compositions, useful as inhibitors of JAK and other protein kinases

IN Bethiel, Randy S.; Moon, Young Choon

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041810	A1	20040521	WO 2003-US35188	20031105
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507406	AA	20040521	CA 2003-2507406	20031105
	US 2004176271	A1	20040909	US 2003-702113	20031105
	EP 1560824	A1	20050810	EP 2003-778111	20031105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-424043P	P	20021105		
	WO 2003-US35188	W	20031105		
OS	MARPAT 140:423692				
AB	The invention provides compds. of formula I or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compns. comprising I, and methods of utilizing I and their compns. in the treatment of various protein kinase-mediated disorders. In compds. I, R1 is Q-Arl; Q is a bond or C1-2 alkylidene chain wherein one methylene unit is optionally replaced by O, NR, NRCO, NRCONR, NRCO2, CO, CO2, CONR, OC(O)NR, SO2, SO2NR, NRSO2, NRSO2NR, C(O)C(O), or C(O)CH2C(O); R is H or (un)substituted aliphatic; Arl is (un)substituted, (poly)(un)saturated, 5- to 7-membered monocyclic ring having 0-3 N/O/S heteroatoms, or 8- to 12-membered bicyclic ring system having 0-5 N/O/S heteroatoms; Z1 is N or CH; Z7 is N or CURy; T, U are bond or (un)saturated C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRRRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; Rx, Ry are independently halogen, CN, NO2, or R'; Z2, Z5, and Z6 are independently N or CH, provided that no more than 2 of them are N; Z3 is CR3; Z4 is CR4; wherein one of R3 and R4 is Ru and the other is OR'; Ru is (CH2)tCN, (CH2)tNO2, (CH2)tNR2, (CH2)tNRCOR, (CH2)tCONR2, (CH2)tCO2R, (CH2)tAr2, etc.; t is 0-2; Ar2 is an (un)substituted, (poly)(un)saturated 5- to 7-membered, monocyclic ring having 0-3 N/O/S heteroatoms; and R' is H, (un)substituted aliphatic or (bi)(hetero)cyclic. Approx. 190 compds. I are claimed individually. A general multi-step preparation is described in examples, including step combinations and final product mol. wts. for approx. 30 invention compds., including II. In a JAK3 inhibition assay, several invention compds. had Ki values less than 0.1 µM. Similar				


potencies were obtained for some compds. against CDK2, JNK3, SYK, and GSK-3.

IT 691895-11-1P 691895-12-2P 691895-13-3P  
 691895-14-4P 691895-15-5P 691895-16-6P  
 691895-17-7P 691895-18-8P 691895-19-9P  
 691895-23-5P 691895-24-6P 691895-25-7P  
 691895-26-8P 691895-27-9P 691895-28-0P  
 691895-29-1P 691895-30-4P 691895-31-5P  
 691895-32-6P 691895-33-7P 691895-34-8P  
 691895-35-9P 691895-36-0P 691895-37-1P  
 691895-38-2P 691895-39-3P 691895-40-6P  
 691895-42-8P 691895-44-0P 691895-45-1P  
 691895-46-2P 691895-47-3P 691895-48-4P  
 691895-49-5P 691895-50-8P 691895-51-9P  
 691895-52-0P 691895-53-1P 691895-54-2P  
 691895-55-3P 691895-56-4P 691895-57-5P  
 691895-58-6P 691895-59-7P 691895-60-0P  
 691895-61-1P 691895-62-2P 691895-63-3P  
 691895-64-4P 691895-65-5P 691895-66-6P  
 691895-67-7P 691895-68-8P 691895-69-9P  
 691895-70-2P 691895-71-3P 691895-72-4P  
 691895-73-5P 691895-74-6P 691895-75-7P  
 691895-76-8P 691895-77-9P 691895-78-0P  
 691895-79-1P 691895-80-4P 691895-81-5P  
 691895-82-6P 691895-83-7P 691895-84-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyridine and pyrimidine derivs. as inhibitors of JAK and other protein kinases)

RN 691895-11-1 CAPIUS  
 CN Benzamide, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-12-2 CAPIUS  
 CN Benzoic acid, 2-hydroxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-13-3 CAPIUS  
 CN Benzamide, 2-hydroxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

NAME)




RN 691895-14-4 CAPIUS

CN Benzamide, 2-hydroxy-N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)


RN 691895-15-5 CAPIUS

CN Benzoic acid, 5-[2-[(3-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 691895-16-6 CAPIUS


CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 691895-17-7 CAPLUS  
 CN Benzoic acid, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]-, methyl ester  
 (9CI) (CA INDEX NAME)




RN 691895-18-8 CAPLUS  
 CN Benzamide, 5-[2-[[3-(aminosulfonyl)phenyl]amino]-4-pyrimidinyl]-2-hydroxy-  
 (9CI) (CA INDEX NAME)




RN 691895-19-9 CAPLUS  
 CN Benzoic acid, 2-methoxy-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA  
 INDEX NAME)




RN 691895-23-5 CAPIUS

CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-hydroxy-  
(9CI) (CA INDEX NAME)

RN 691895-24-6 CAPIUS


CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)  
(CA INDEX NAME)

RN 691895-25-7 CAPIUS


CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)  
(CA INDEX NAME)

RN 691895-26-8 CAPIUS


CN Benzamide, 5-[2-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl]-2-hydroxy-  
(9CI) (CA INDEX NAME)




RN 691895-27-9 CAPLUS  
 CN Benzamide, 2-hydroxy-5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 691895-28-0 CAPLUS  
 CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-hydroxy- (9CI)  
 (CA INDEX NAME)




RN 691895-29-1 CAPLUS  
 CN Benzamide, 5-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)  
 (CA INDEX NAME)




RN 691895-30-4 CAPIUS  
 CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)  
 (CA INDEX NAME)




RN 691895-31-5 CAPIUS  
 CN Benzamide, 2-methoxy-5-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 691895-32-6 CAPIUS  
 CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)  
 (CA INDEX NAME)




RN 691895-33-7 CAPIUS  
 CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 691895-34-8 CAPIJS  
 CN Benzamide, 5-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)  
 (CA INDEX NAME)




RN 691895-35-9 CAPIUS  
 CN Benzamide, 5-[2-[(3-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl]-2-methoxy-  
 (9CI) (CA INDEX NAME)



RN 691895-36-0 CAPIUS


CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-methoxy-  
(9CI) (CA INDEX NAME)

RN 691895-37-1 CAPIUS


CN Benzamide, 5-[2-[(3,4-dimethylphenyl)amino]-4-pyrimidinyl]-2-methoxy-  
(9CI) (CA INDEX NAME)

RN 691895-38-2 CAPIUS


CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-methoxy- (9CI)  
(CA INDEX NAME)



RN 691895-39-3 CAPIUS


CN Benzoic acid, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy-,  
methyl ester (9CI) (CA INDEX NAME)

RN 691895-40-6 CAPIUS


CN Benzoic acid, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy-  
(9CI) (CA INDEX NAME)

RN 691895-42-8 CAPIUS


CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-ethoxy- (9CI)  
(CA INDEX NAME)




RN 691895-44-0 CAPIUS  
 CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-propoxy- (9CI) (CA INDEX NAME)




RN 691895-45-1 CAPIUS  
 CN Benzamide, 2-(1-methylethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-46-2 CAPIUS  
 CN Benzamide, 2-(cyclohexylmethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-47-3 CAPIUS  
 CN Benzamide, 2-(cyclopropylmethoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-48-4 CAPLUS  
 CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 691895-49-5 CAPLUS  
 CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-50-8 CAPLUS  
 CN Benzamide, 2-[(3-methoxyphenyl)methoxy]-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-51-9 CAPIUS  
 CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-52-0 CAPIUS  
 CN Benzamide, 2-(2-methylpropoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-53-1 CAPIUS  
 CN Benzamide, 2-(2-ethylbutoxy)-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-54-2 CAPIUS  
 CN Benzamide, 5-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-55-3 CAPIUS  
 CN Benzamide, 5-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-  
 (9CI) (CA INDEX NAME)




RN 691895-56-4 CAPIUS  
 CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-  
 (9CI) (CA INDEX NAME)




RN 691895-57-5 CAPIUS  
 CN Benzamide, 5-[2-[(3-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)-  
 (9CI) (CA INDEX NAME)




RN 691895-58-6 CAPIUS  
 CN Benzamide, 5-[2-[(3,5-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-59-7 CAPIUS  
 CN Benzamide, 5-[2-[(3-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-60-0 CAPIUS  
 CN Benzamide, 5-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-61-1 CAPIUS  
 CN Benzoic acid, 3-[[4-(3-(aminocarbonyl)-4-(1-methylethoxy)phenyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 691895-62-2 CAPIUS  
 CN Benzamide, 2-(1-methylethoxy)-5-[2-[(4-(4-morpholinyl)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-63-3 CAPIUS  
 CN Benzamide, 2-(1-methylethoxy)-5-[2-[(3-phenoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 691895-64-4 CAPIUS

CN Benzamide, 5-[2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-65-5 CAPIUS

CN Benzamide, 5-[2-[(3-chlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-66-6 CAPIUS

CN Benzamide, 5-[2-[(3,4-difluorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 691895-67-7 CAPIUS

CN Benzamide, 5-[2-[(4-chloro-3-cyanophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 691895-68-8 CAPIUS


CN Benzamide, 5-[2-[(3,5-dichlorophenyl)amino]-4-pyrimidinyl]-2-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 691895-69-9 CAPIUS

CN Benzoic acid, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 691895-70-2 CAPIUS

CN Benzoic acid, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3*R*)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-71-3 CAPIUS


CN Benzoic acid, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3*S*)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 691895-72-4 CAPIUS


CN Benzoic acid, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 691895-73-5 CAPIUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 691895-74-6 CAPIUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl-2-[(3R)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 691895-75-7 CAPIUS

CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 691895-76-8 CAPIUS

CN Benzamide, N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3R)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 691895-77-9 CAPIUS


CN Benzamide, 5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 691895-78-0 CAPLUS

CN Benzamide, N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 691895-79-1 CAPLUS


CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-2-[(3S)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**


RN 691895-80-4 CAPLUS

CN Benzamide, 5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl-2-[(3S)-tetrahydro-3-furanyl]oxy- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 691895-81-5 CAPIUS


CN Benzamide, 2-methoxy-N-methyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

RN 691895-82-6 CAPIUS

CN Benzamide, 2-methoxy-N,N-dimethyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)


RN 691895-83-7 CAPIUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 691895-84-8 CAPLUS

CN Benzamide, 2-methoxy-5-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 29 CAPIUS COPYRIGHT 2005 ACS on STN  
 AN 2004:412924 CAPIUS  
 DN 140:423690  
 TI Pyridine and pyrimidine derivatives and their compositions, useful as inhibitors of JAK and other protein kinases  
 IN Ledeboer, Mark; Ledford, Brian  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041789	A1	20040521	WO 2003-US34991	20031103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506772	AA	20040521	CA 2003-2506772	20031103
	US 2004147507	A1	20040729	US 2003-700333	20031103
	EP 1562911	A1	20050817	EP 2003-778092	20031103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-422973P	P	20021101		
	WO 2003-US34991	W	20031103		

OS MARPAT 140:423690

AB The invention provides a compound of formula I or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compns. comprising I, and methods of utilizing I and their compns. in the treatment of various protein kinase-mediated disorders. In compds. I, R1 is Q-Arl; Q is a C1-2 alkylidene chain wherein one methylene unit is optionally replaced by O, NR, NRCO, NRCONR, NRCO2, CO, CO2, CONR, OC(O)NR, SO2, SO2NR, NRSO2, NRSO2NR, C(O)C(O), or C(O)CH2C(O); R is H or (un)substituted aliphatic; Arl is (un)substituted, (poly)(un)saturated, 5- to 7-membered monocyclic ring having 0-3 N/O/S heteroatoms, or 8- to 12-membered bicyclic ring system having 0-5 N/O/S heteroatoms; Z1 is N or CH; Z7 is N or C(U)nRy; T, U are bond or (un)saturated C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRRRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; m, n are independently 0 or 1; Rx, Ry are independently R or Arl; Z2 is N or CR2; Z3 is N or CR3; Z4 is N or CR4; Z5 is N or CR5; and Z6 is N or CR6; wherein each occurrence of R2, R3, R4, R5, or R6 is independently Ru or (V)pRv, provided that (a) no more than 3 of Z2, Z3, Z4, Z5 or Z6 are N, and (b) at least one of Z3, Z4 or Z5 is CR3, CR4, or CR5, resp., and at least one of R3, R4, or R5 is Ru, each occurrence of Ru is NRCOR7, CONR(R7), SO2NR(R7), NRSO2R7, NRCONR(R7), NRSO2NR(R7), or CONRNR(R7), wherein R7 is (CH2)t-Y-R8; and t is 0-2. Furthermore, Y is bond, O, S, NR9, OCH2, SCH2, NR9CH2, O(CH2)2, S(CH2)2, or NR9(CH2)2; R5 is Ar2, or NR8R9 is (un)substituted 5- to 8-membered heterocyclyl or heteroaryl having 1-3 N/O/S heteroatoms; each occurrence of V is bond or (un)saturated


C1-6 alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNR<sub>2</sub>, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR; each occurrence of p is 0 or 1; each occurrence of R<sub>v</sub> is R or Ar<sub>2</sub>; and Ar<sub>2</sub> is an (un)substituted, (poly)(un)saturated 5- to 7-membered, monocyclic ring having 0-3 N/O/S heteroatoms, or an 8- to 12-membered, bicyclic ring system having 0-5 N/O/S heteroatoms. It is further provided that: (a) when Z<sub>1</sub> is N, and Z<sub>7</sub> is CH, and ring B is Ph, and at least one of R<sub>3</sub> or R<sub>4</sub> is NHCOR<sub>7</sub>, then R<sub>1</sub> is not Ph which is only substituted with two or three occurrences of OR'; and also that (b) when Z<sub>1</sub> is N, and Z<sub>7</sub> is CH, and ring B is Ph, and at least one of R<sub>3</sub> or R<sub>4</sub> is NHCOR<sub>7</sub>, SO<sub>2</sub>R<sub>7</sub>, or CONRR<sub>7</sub>, then R<sub>1</sub> is not Ph which is only substituted with one occurrence of -CON(R')<sub>2</sub> in the para-position, where R' is H, (un)substituted aliphatic or (bi)(hetero)cyclic. Approx. 100 compds. I are claimed individually, and several compds. were prepared in examples. For instance, 3-aminoacetophenone was amidated with 2-furoyl chloride, and the resultant N-(3-acetylphenyl)amide underwent condensation with DMF di-Me acetal at the acetyl Me group, with partial N-methylation at the amide. Cyclocondensation of the resultant mixture of β-(dimethylamino)-α,β-unsatd. ketones with (3-methoxyphenyl)guanidine gave a mixture of invention compds. II [R = H, Me]. In a JAK3 inhibition assay, several invention compds. including II [R = Me] had Ki values of 1.0 μM or less. Similar potencies were obtained for some compds. against CDK2, JNK3, and (no data) ZAP-70.

IT 692733-87-2P 692733-88-3P 692733-89-4P  
 692733-90-7P 692733-91-8P 692733-92-9P  
 692733-93-0P 692733-94-1P 692733-95-2P  
 692733-96-3P 692733-97-4P 692733-98-5P  
 692733-99-6P 692734-00-2P 692734-01-3P  
 692734-02-4P 692734-03-5P 692734-04-6P  
 692734-05-7P 692734-06-8P 692734-07-9P  
 692734-08-0P 692734-09-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridine and pyrimidine derivs. as inhibitors of JAK and other protein kinases)


RN 692733-87-2 CAPLUS  
 CN Piperidine, 1-[2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 692733-88-3 CAPLUS  
 CN Benzamide, 2-methyl-N-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692733-89-4 CAPIUS  
 CN Benzamide, N-cyclohexyl-2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 692733-90-7 CAPIUS  
 CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)-  
 (9CI) (CA INDEX NAME)




RN 692733-91-8 CAPIUS  
 CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(2-  
 pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-92-9 CAPIUS  
 CN Benzamide, 2-methyl-5-[2-(phenylamino)-4-pyrimidinyl]-N-(3-  
 pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-93-0 CAPLUS  
 CN Benzamide, N-(cyclohexylmethyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 692733-94-1 CAPLUS  
 CN Benzamide, N-(2-furanyl methyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)



RN 692733-95-2 CAPLUS  
 CN Benzamide, N-(1-naphthalenylmethyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692733-96-3 CAPLUS  
 CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-97-4 CAPIUS

CN Benzamide, N-[(2,3-dichlorophenyl)methyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692733-98-5 CAPIUS

CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 692733-99-6 CAPIUS

CN Benzamide, N-[2-(1H-imidazol-4-yl)ethyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-00-2 CAPIUS

CN Benzamide, N-[(2,5-difluorophenyl)methyl]-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-01-3 CAPIUS

CN Benzamide, 3-[2-(phenylamino)-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 692734-02-4 CAPIUS

CN Piperidine, 1-[4-[2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 692734-03-5 CAPIUS

CN Benzamide, 4-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 692734-04-6 CAPIUS


CN Benzamide, N-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-05-7 CAPIUS  
 CN Benzamide, N-cyclohexyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 692734-06-8 CAPIUS  
 CN Benzamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 692734-07-9 CAPIUS  
 CN Piperidine, 1-[4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 692734-08-0 CAPIUS  
 CN Benzamide, 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 692734-09-1 CAPIUS

CN Benzamide, N-cyclohexyl-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



L8 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:162676 CAPLUS

DN 140:199343:

TI Preparation of aminopyrimidine derivatives as protein kinase inhibitors

IN Cochran, John; Green, Jeremy; Hale, Michael R.; Ledford, Brian; Maltais, Francois; Nanthakumar, Suganthini

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN, CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016597	A2	20040226	WO 2003-US25333	20030812
	WO 2004016597	A3	20040422		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495386	AA	20040226	CA 2003-2495386	20030812
	US 2004106615	A1	20040603	US 2003-639784	20030812
	BR 2003013397	A	20050628	BR 2003-13397	20030812
	EP 1546117	A2	20050629	EP 2003-788433	20030812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	NO 2005001207	A	20050518	NO 2005-1207	20050308
PRAI	US 2002-403256P	P	20020814		
	US 2002-416802P	P	20021008		
	WO 2003-US25333	W	20030812		


OS MARPAT 140:199343

AB Title compds. I [wherein B = 6-membered aryl ring with 0-3 N atoms, Z1, Z2 = independently N, CH; T, Q = independently saturated or unsatd. alkylidene; U = NH and derivs., NHCO2 and derivs., o, CONH and derivs., CO, CO2, OCO, NHSO2 and derivs., SO2NH and derivs., SO2, etc.; m, n = independently 0 or 1; p = 0-4; R1 = R or Ar; R = H, (un)substituted aliphatic group; Ar = (un)substituted 6-10 membered aryl ring, 5-10 membered heteroaryl ring having 1-4 heteroatoms, or a 3-10 heterocyclyl membered ring having 1-4 heteroatoms; R3 = R, Ar, (CH2)yCH(R5)2 or CN; y = 0-6; R2 = (CH2)yCH(R5)2, (CH2)yCH(R4)CH(R5)2; R4 = R, (CH2)wOR, (CH2)wN(R)2 or (CH2)wSR; w = 0-4; R5 = independently Ar, OR, CO2R, SR, SO2R, CN, N(Ar)(R), (un)substituted aliphatic, etc.; R6 = independently R, F, Cl, NH2 and derivs., OR, SR, SO2R, NRSO2R, CN, SO2N(R)2, etc.; and their pharmaceutically acceptable salts] were prepared as protein kinase inhibitors (no data). For example, II was prepared in 3 steps by Pd-cross coupling of 2,4-dichloro-5-fluoropyrimidine with 4-methoxycarbonylphenyl boronic acid (III); acylation of (S)-3-chlorophenyl glycinol with III, and alkylation of isopropylamine with 2-chloropyrimidine intermediate. I and their formulations are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE, lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation (no data).

Appl.  
PCG


IT 663611-45-8P, 3-[2-(Phenylamino)pyrimidin-4-yl]benzoic acid  
 663611-50-5P 663611-51-6P 663611-63-0P  
 663611-64-1P 663611-66-3P, 4-[5-Chloro-2-(cyclopropylamino)pyrimidin-4-yl]benzoic acid methyl ester  
 663611-67-4P, 4-[5-Chloro-2-(cyclopropylamino)pyrimidin-4-yl]benzoic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)

RN 663611-45-8 CAPLUS  
 CN Benzoic acid, 3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 663611-50-5 CAPLUS  
 CN Benzoic acid, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663611-51-6 CAPLUS  
 CN Benzoic acid, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-63-0 CAPLUS

CN Benzoic acid, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 663611-64-1 CAPLUS

CN Benzoic acid, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 663611-66-3 CAPIUS  
 CN Benzoic acid, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 663611-67-4 CAPIUS  
 CN Benzoic acid, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 216959-98-7, 4-(2-Aminopyrimidin-4-yl)benzoic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)  
 RN 216959-98-7 CAPIUS  
 CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




IT 663611-53-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (protein kinase inhibitor; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)  
 RN 663611-53-8 CAPLUS  
 CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 663611-48-1P 663611-52-7P 663611-57-2P  
 663611-59-4P 663611-62-9P 663611-65-2P  
 663611-71-0P 663611-74-3P 663611-75-4P  
 663611-77-6P 663611-82-3P 663611-84-5P  
 663612-19-9P 663612-20-2P 663612-21-3P  
 663612-22-4P 663612-23-5P 663612-24-6P  
 663612-25-7P 663612-27-9P 663612-28-0P  
 663612-29-1P 663612-30-4P 663612-31-5P  
 663612-32-6P 663612-33-7P 663612-34-8P  
 663612-35-9P 663612-42-8P 663612-81-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; preparation of 6-membered heterocycles, in particular aminopyrimidines as protein kinase inhibitors)  
 RN 663611-48-1 CAPLUS  
 CN Benzamide, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




*Elected Species*

RN 663611-52-7 CAPIUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-57-2 CAPIUS

CN Benzamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-59-4 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-62-9 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-65-2 CAPLUS

CN Benzamide, 4-[5-chloro-2-(cyclopropylamino)-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-71-0 CAPLUS


CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 663611-74-3 CAPLUS


CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 663611-75-4 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-3-methyl- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 663611-77-6 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-methyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 663611-82-3 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663611-84-5 CAPLUS

CN Benzamide, 4-[5-chloro-2-(ethoxyamino)-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-19-9 CAPLUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663612-20-2 CAPIUS

CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 663612-21-3 CAPIUS


CN Benzamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 663612-22-4 CAPIUS


CN Benzamide, 4-[5-chloro-2-[(1-methylethyl)amino]-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 663612-23-5 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**

RN 663612-24-6 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**

RN 663612-25-7 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-2-

hydroxy-1-methylethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-27-9 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-28-0 CAPLUS

CN Benzamide, 4-[5-fluoro-2-[(1-methylethyl)amino]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-29-1 CAPIUS

CN Benzamide, 4-[5-fluoro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-30-4 CAPIUS

CN Benzamide, 4-[2-(cyclopropylamino)-5-fluoro-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663612-31-5 CAPIUS

CN Benzamide, 4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-

pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-32-6 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-33-7 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-34-8 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-35-9 CAPLUS

CN Benzamide, 4-[2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 663612-42-8 CAPLUS

CN Benzamide, 4-[5-chloro-2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 663612-81-5 CAPLUS

CN Benzamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-fluoro-2-[(1S)-2-hydroxy-1-methylethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



L8 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:837045 CAPLUS  
 DN 139:337995  
 TI Preparation of benzamides as histone deacetylase inhibitors  
 IN Stokes, Elaine Sophie Elizabeth; Roberts, Craig Anthony; Waring, Michael James  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087057	A1	20031023	WO 2003-GB1442	20030402
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480356	AA	20031023	CA 2003-2480356	20030402
	BR 2003008875	A	20050104	BR 2003-8875	20030402
	EP 1495002	A1	20050112	EP 2003-712442	20030402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005171103	A1	20050804	US 2003-509941	20030402
	JP 2005533011	T2	20051104	JP 2003-584013	20030402
	NO 2004004444	A	20041228	NO 2004-4444	20041019
PRAI	GB 2002-7863	A	20020405		
	GB 2002-29930	A	20021221		
	WO 2003-GB1442	W	20030402		
OS	MARPAT 139:337995				
AB	The title compds. [I; ring A = heterocyclyl; m = 0-4; R1 = OH, halo, CF3, CN, etc.; R2 = halo; n = 0-2; R3 = NH2, OH; R4 = OH, halo, CF3, CN, etc.; p = 0-4; or pharmaceutically-acceptable salts or in-vivo-hydrolysable esters or amides thereof], useful in the treatment of diseases or medical conditions mediated by histone deacetylase such as cancer, were prepared Thus, deprotection of N-(2-tert-butoxycarbonylaminophenyl)-4-(pyridin-4-yl)benzamide (preparation given) with 4M HCl solution in dioxane afforded 46% I.HCl [A = pyridin-4-yl; R2 = H; R3 = NH2; R4 = H]. The compds. I showed IC50 of < 50.0 µM in in vitro enzyme assay of pooled histone deacetylases. Pharmaceutical composition comprising the compound I is claimed.				
IT	617702-02-0P 617702-08-6P 617702-09-7P 617702-10-0P 617702-11-1P 617702-12-2P 617702-13-3P 617702-14-4P 617702-15-5P 617702-16-6P 617702-17-7P 617702-39-3P 617702-40-6P 617702-41-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of benzamides as histone deacetylase inhibitors)				
RN	617702-02-0 CAPLUS				
CN	Benzamide, N-(2-aminophenyl)-4-(2-amino-4-pyrimidinyl)-, hydrochloride				


(9CI) (CA INDEX NAME)



● x HCl


RN 617702-08-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-(4-morpholinyl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 617702-09-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 617702-10-0 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-(1-piperidinyl)propyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 617702-11-1 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 617702-12-2 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 617702-13-3 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[(4-(diethylamino)butyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 617702-14-4 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[2-[(2-(diethylamino)ethyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 617702-15-5 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 617702-16-6 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(1-piperidinyl)ethyl]amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 617702-17-7 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 617702-39-3 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-[2-(dimethylamino)ethoxy]propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 617702-40-6 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[(3-(methylphenylamino)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 617702-41-7 CAPLUS  
 CN Benzamide, N-(2-aminophenyl)-4-[2-[(2-(dibutylamino)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 617702-97-3P 617703-05-6P 617703-06-7P  
 617703-09-0P 617703-10-3P 617703-11-4P  
 617703-12-5P 617703-13-6P 617703-14-7P  
 617703-15-8P 617703-16-9P 617703-17-0P  
 617703-18-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of benzamides as histone deacetylase inhibitors)


RN 617702-97-3 CAPLUS

CN Carbamic acid, [2-[[4-(2-amino-4-pyrimidinyl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-05-6 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 617703-06-7 CAPLUS

CN Carbamic acid, [2-[[4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-09-0 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



## ●3 HCl


RN 617703-10-3 CAPLUS

CN Carbamic acid, [2-[4-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-11-4 CAPLUS

CN Carbamic acid, [2-[4-[2-[(3-(1-piperidinyl)propyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-12-5 CAPLUS

CN Carbamic acid, [2-[4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-13-6 CAPLUS

CN Carbamic acid, [2-[(4-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-14-7 CAPLUS

CN Carbamic acid, [2-[(4-[2-[(4-(diethylamino)butyl]amino)-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-15-8 CAPLUS


CN Carbamic acid, [2-[(4-[2-[(2-(diethylamino)ethyl]amino)-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 617703-16-9 CAPLUS  
 CN Carbamic acid, [2-[4-[2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-17-0 CAPLUS  
 CN Carbamic acid, [2-[4-[2-[(2-(1-piperidinyl)ethyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 617703-18-1 CAPLUS  
 CN Carbamic acid, [2-[4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl]benzoyl]amino]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:633697 CAPLUS  
 DN 139:180090  
 TI Preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for the treatment of neurological disorders  
 IN Adam, Geo; Goetschi, Erwin; Wichmann, Juergen; Woltering, Thomas Johannes  
 PA F. Hoffmann-La Roche A.-G., Switz.  
 SO PCT Int. Appl., 323 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066623	A1	20030814	WO 2003-EP859	20030128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003166639	A1	20030904	US 2003-350713	20030124
	US 6949542	B2	20050927		
	CA 2474219	AA	20030814	CA 2003-2474219	20030128
	BR 2003007474	A	20041109	BR 2003-7474	20030128
	EP 1474416	A1	20041110	EP 2003-702549	20030128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005522440	T2	20050728	JP 2003-565996	20030128
	NO 2004003237	A	20040802	NO 2004-3237	20040802
PRAI	EP 2002-2012	A	20020206		
	WO 2003-EP859	W	20030128		

OS MARPAT 139:180090

AB This invention relates to dihydrobenzo[b][1,4]diazepin-2-ones (shown as I; variables defined below; e.g. 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one). The invention further relates to medicaments containing these compds., a process for their preparation as well as


their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurol. disorders, e.g. Alzheimer's disease. Three examples of pharmaceutical compns. containing I are included. Ki values for 50 examples of I as metabotropic glutamate receptor antagonists are tabulated, e.g. 0.00135  $\mu$ M for 7,8-dichloro-4-(3-pyridin-3-ylphenyl)-1,3-dihydrobenzo[b][1,4]diazepin-2-one. More than 400 example preps. of I and many example preps. of intermediates are included. For example, 7,8-dichloro-4-[3-(pyridin-3-yl)phenyl]-1,3-dihydrobenzo[b][1,4]diazepin-2-one (310 mg) was prepared from 4,5-dichlorophenylenediamine (0.97 mmol) and 3-oxo-3-[3-(pyridin-3-yl)phenyl]propionic acid tert-Bu ester (0.97 mmol) by refluxing in xylene. For I: X is a single bond or an ethynediyl group; and wherein in case X is a single bond, R1 is H, cyano, halogen, lower alkyl, lower alkoxy, fluoro-lower alkyl, fluoro-lower alkoxy, pyrrol-1-yl, or Ph, which is (un)substituted by one or two substituents halogen, lower alkyl or fluoro-lower alkyl; or in case X is an ethynediyl group, R1 is Ph, which is (un)substituted by one or two substituents halogen, lower

alkyl or fluoro-lower alkyl. R2 is H, lower alkyl, lower alkenyl lower alkoxy, halogen, -NR'R'', pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, fluoro-lower alkyl, fluoro-lower alkoxy, or lower alkoxy(ethoxy)<sup>m</sup>; m = 1-4; R' is H, lower alkyl or C3-C6-cycloalkyl; R'' is H, lower alkyl or C3-C6-cycloalkyl; Y is -CH= or =N-; R3 is a six-membered aromatic heterocycle containing 1 to 3-N atoms or a pyridine N-oxide, which rings are (un)substituted by one or two substituents halogen, fluoro-lower alkyl, fluoro-lower alkoxy, cyano, amino, lower alkylamino, lower alkoxy-lower alkylamino, lower hydroxy-lower alkylamino, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-OR'', -(CH<sub>2</sub>)<sub>n</sub>-C(O)-NR'R'', -(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>-NR'R'', -(CH<sub>2</sub>)<sub>n</sub>-C(NH<sub>2</sub>):NR'', hydroxy, lower alkoxy, lower alkylthio, C3-C6-cycloalkyl and lower alkyl, which is (un)substituted by fluoro, -NR'R'', hydroxy, lower alkoxy, pyrrolidin-1-yl, azetidin-1-yl, cyano or carbamoyloxy; n = 0-4.

IT 579476-49-6P, 3-(2-Aminopyrimidin-4-yl)benzoic acid methyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of dihydrobenzodiazepin-2-ones as metabotropic glutamate receptor antagonists for treatment of neurol. disorders)

RN 579476-49-6 CAPLUS

CN Benzoic acid, 3-(2-amino-4-pyrimidinyl)-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:300895 CAPLUS  
 DN 138:321288  
 TI Preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring for use as kinase inhibitors in the treatment of cancer  
 IN Nagarathnam, Dhanapalan; Wang, Chunguang; Chen, Yuanwei; Yi, Lin; Chen, Jianqing; Weber, Olaf; Boyer, Stephen; Clark, Roger B.; Phillips, Barton; Meahl, Jennifer; Ladouceur, Gaetan; Bi, Cheng; Burke, Michael J.; Cook, James; Verma, Sharad K.; Fan, Jianmei  
 PA Bayer Corporation, USA  
 SO PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030909	A1	20030417	WO 2002-US30616	20020925
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-324276P	P	20010925		
	US 2002-352509P	P	20020131		
OS	MARPAT 138:321288				
AB	The title compds. [I; X = NR1R6, NR4R5, R4, with the proviso that at least one X must be NR1R6; R1 = (un)substituted fused bicyclic unsatd. ring containing 9 or 10 atoms optionally containing 1-4 heteroatoms selected from the group consisting of N, S and O; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, thio; R4 = (un)substituted -Yn-mono-ring group or -Yn-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylenyl, C(CN); R4 can also be hydrogen or alkyl when R5 is present); R5 = (un)substituted -Yn-mono-ring group or -Yn-multi-ring group (each ring containing 4-18 atoms in the ring and optionally containing 1-4 heteroatoms selected from N, S, and O; n = 0-1; Y = alkylenyl, N:CH, N:CHMe; with the proviso that the multi-ring group cannot be benzimidazolyl); R6 = H, alkyl] which are kinase inhibitors useful in the treatment of cancer and viral infections, were prepared and formulated. Thus, heating 6-aminoquinoline with 2,4-dichloro-5-trifluoromethylpyrimidine (preparation given) in the presence of Na2CO3 in BuOH to 120°C for 3 days afforded I [X = 6-quinolinylamino; R2 = CF3; R3 = H] which showed IC50 of 0.48 μM in in vitro proliferation inhibition assay (HCT 116 human colorectal carcinoma cells). IT 511248-67-2P RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)				
RN	511248-67-2 CAPLUS				

CN Benzoic acid, 4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)




IT 511244-94-3P 511245-08-2P 511248-71-8P  
511248-82-1P 511248-83-2P 511248-87-6P  
511248-99-0P 511249-07-3P 511249-08-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)


RN 511244-94-3 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 511245-08-2 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 511248-71-8 CAPLUS


CN Ethanone, 1-[3-[5-fluoro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 511248-82-1 CAPLUS


CN Ethanone, 1-[4-[2-(6-quinolinylamino)-5-(trifluoromethyl)-4-

pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-83-2 CAPLUS

CN Ethanone, 1-[4-[5-chloro-2-(6-quinolinylamino)-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-87-6 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511248-99-0 CAPLUS

CN Ethanone, 1-[4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 511249-07-3 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)



RN 511249-08-4 CAPLUS

CN Benzoic acid, 4-[5-fluoro-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:814853 CAPLUS  
 DN 137:325431  
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors  
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manjo; Levine, Barry H.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. 6,417,185.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156087	A1	20021024	US 2001-949035	20010906
	US 6417185	B1	20020709	US 1999-336038	19990618
PRAI	US 1999-336038	A2	19990618		
	US 2000-230480P	P	20000906		
	US 1998-89978P	P	19980619		
OS	MARPAT 137:325431				
AB	Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO <sub>2</sub> , (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H <sub>2</sub> N(CH <sub>2</sub> ) <sub>3</sub> NH <sub>2</sub> and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C <sub>6</sub> H <sub>4</sub> CONHCH <sub>2</sub> C <sub>6</sub> H <sub>4</sub> Br-3 and Cs <sub>2</sub> CO <sub>3</sub> to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free assay with IC <sub>50</sub> values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).				
IT	252904-09-9P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- 252904-11-3P, Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-13-5P, Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-31-7P, Benzamide, 4-[2-[[2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-32-8P, Benzamide, 4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- 252904-33-9P, Benzamide, 4-[2-[[2-(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- 252904-34-0P, Benzamide, 4-[2-[[3-(1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- 252904-35-1P, Benzamide, 4-[2-[[3-(2-naphthalenyl)propyl]amino]-4-pyrimidinyl]- 252904-36-2P				

Same  
as  
#17


4-pyrimidinyl]- 252904-36-2P, Benzenepropanamide,  
 $\alpha$ -[(4-[2-[(2-pyridinyl)ethyl]amino]-4-pyrimidinyl)benzoyl]amino]-  
 $\alpha$ -( $\alpha$ S)-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase  
 3 inhibitors)


RN 252904-09-9 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(3-[(5-nitro-2-pyridinyl)amino]propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-11-3 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(5-cyano-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS

CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


$\text{--OMe}$

RN 252904-31-7 CAPLUS


CN Benzamide, 4-[2-[(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-32-8 CAPLUS  
 CN Benzamide, 4-[2-[(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl- (9CI)  
 (CA INDEX NAME)




RN 252904-33-9 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-methoxy-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 252904-34-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-(1H-benzimidazol-1-yl)propyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 252904-35-1 CAPLUS

CN Benzamide, 4-[2-[[3-(2-naphthalenyl)oxy]propyl]amino]-4-pyrimidinyl- (9CI)  
(CA INDEX NAME)

RN 252904-36-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[4-[[2-[[2-pyridinyl]ethyl]amino]-4-pyrimidinyl]benzoyl]amino]-, ( $\alpha S$ )- (9CI) (CA INDEX NAME)**Absolute stereochemistry.**IT 403806-71-3, 4-[2-[(4-Pyridylmethyl)amino]pyrimidin-4-yl]benzamide  
403806-72-4 403806-74-6, 4-[2-[(3-Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-75-7,  
4-[2-[(4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
403806-76-8, 4-[2-[(5-Methylpyrazin-2-yl)methyl]amino]pyrimidin-4-yl]benzamide 403806-78-0, 4-[2-[(3-Imidazolylpropyl)amino]pyrimidin-4-yl]benzamide 403806-80-4, 4-[2-[(4-

Page 108


Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-81-5**,  
 4-[2-[(3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403806-82-6**, 4-[2-[(4-Methoxyphenyl)methyl]amino]pyrimidin-4-  
 yl]benzamide **403806-83-7**, 4-[2-[(2-(4-  
 Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403806-87-1**,  
 4-[2-[(3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403806-92-8**, 4-[2-[(4-Phenylbutyl)amino]pyrimidin-4-yl]benzamide  
**403806-94-0**, 4-[2-[(2-(3-Methoxyphenyl)ethyl]amino]pyrimidin-4-  
 yl]benzamide **403806-96-2**, 4-[2-[(3-Phenoxypropyl)amino]pyrimidin-  
 4-yl]benzamide **403806-98-4**, 4-[2-[(3-  
 Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-02-3**,  
 4-[2-[(2-(3-Chlorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide  
**403807-03-4**, 4-[2-[(Naphthylmethyl)amino]pyrimidin-4-yl]benzamide  
**403807-10-3**, 4-[2-[(3-(3-Methoxyphenoxy)propyl]amino]pyrimidin-4-  
 yl]benzamide **403807-11-4**, 4-[2-[(2-(2H-Benzo[3,4-d]-1,3-dioxolan-  
 5-yl)ethyl]amino]pyrimidin-4-yl]benzamide **403807-12-5**,  
 4-[2-[(2-(4-Nitrophenyl)ethyl]amino]pyrimidin-4-yl]benzamide  
**403807-13-6**, 4-[2-[(2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-  
 yl]benzamide **403807-14-7**, 4-[2-[(3,4-  
 Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-19-2**  
 , 4-[2-[(3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-20-5**, 4-[2-[(4-(Trifluoromethyl)phenyl)methyl]amino]pyrimi-  
 din-4-yl]benzamide **403807-21-6**, 4-[2-[(3,5-  
 Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-23-8**  
 , 4-[2-[(2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-27-2**, 4-[2-[(3-(3-Methoxyphenoxy)propyl]amino]pyrimidin-4-  
 yl]benzamide **403807-32-9**, 4-[2-[(3-[4-(2,4-  
 Dichlorophenyl)imidazolyl]propyl]amino]pyrimidin-4-yl]benzamide  
**403807-33-0**, 4-[2-[(3-[4-(3-Methoxyphenyl)imidazolyl]propyl]amino]  
 Pyrimidin-4-yl]benzamide **403807-36-3**, 4-[2-[(3-(4-  
 Chlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide **403807-37-4**,  
 4-[2-[(4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-38-5**, 4-[2-[(4-(4-Fluorophenyl)phenyl)methyl]amino]pyrimid-  
 in-4-yl]benzamide **403807-39-6**, 4-[2-[(3-  
 Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-43-2**,  
 4-[2-[(2-(Benzothiazol-2-ylamino)ethyl]amino]pyrimidin-4-yl]benzamide  
**403807-46-5**, 4-[2-[(2,2-Diphenylethyl)amino]pyrimidin-4-  
 yl]benzamide **403807-47-6**, 4-[2-[(3,4,5-  
 Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-49-8**  
 , 4-[2-[(3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-50-1**, 4-[2-[(4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidi-  
 n-4-yl]benzamide **403807-51-2**, 4-[2-[(3-(6-  
 Quinolyl)oxy]propyl]amino]pyrimidin-4-yl]benzamide **403807-56-7**,  
 Ethyl 4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl]amino]pyrimidin-4-  
 yl]benzoate **403807-57-8**, N-Benzyl-4-[2-[(2-  
 pyridyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403807-60-3**  
 , 4-[2-[(3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-62-5**, 4-[2-[(3-(2,4-Dichlorophenoxy)propyl]amino]pyrimidin-  
 4-yl]benzamide **403807-63-6**, 4-[2-[(3-(3,4-  
 Dichlorophenoxy)propyl]amino]pyrimidin-4-yl]benzamide **403807-64-7**  
 , 4-[2-[(3-(3-Phenylphenoxy)propyl]amino]pyrimidin-4-yl]benzamide  
**403807-65-8**, 4-[2-[(3-[3-(Methylamino)methyl]phenyl)phenyl]methy-  
 l]amino]pyrimidin-4-yl]benzamide **403807-68-1**,  
 4-[2-[(3-(3-Bromophenoxy)propyl]amino]pyrimidin-4-yl]benzamide  
**403807-77-2**, N-(2-Methoxyethyl)-4-[2-[(2-[(5-nitro-2-  
 pyridyl)amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403807-78-3**, 4-[2-[(3-[3-(Acetylamino)phenyl]phenyl)methyl]amino]  
 pyrimidin-4-yl]benzamide **403807-79-4**, 4-[2-[(3,5-

Bis(trifluoromethyl)phenylmethylamino]pyrimidin-4-yl]benzamide  
**403807-83-0**, 4-[2-[[3-[3-(Trifluoromethyl)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-90-9**, N-(Oxolan-2-ylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403807-93-2**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide **403807-94-3**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(3-pyridylmethyl)carboxamide **403807-99-8**, N-(2-Thienylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-03-7**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(4-piperidylmethyl)carboxamide **403808-07-1**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylethyl)carboxamide **403808-08-2**, N-[3-Methylphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-11-7**, [4-[2-[[2-[[6-Amino-5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide **403808-12-8**, N-[5-Methylpyrazin-2-yl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-13-9**, N-[3-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-15-1**, N-[4-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-16-2**, [4-[2-[(3-Bromophenyl)methyl]amino]pyrimidin-4-yl]phenyl-N-[3-methylphenyl]carboxamide **403808-18-4**, N-(3-Imidazolylpropyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-19-5** **403808-21-9**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylcyclopropyl)carboxamide **403808-22-0**, N-[4-Methoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-26-4**, N-[3-Chlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-27-5**, N-[3,4-Difluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-30-0**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-[3-nitrophenyl)methyl]carboxamide **403808-32-2**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[(3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-33-3**, N-(Naphthylmethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-37-7**, N-[3,4-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-38-8**, N-[2,3-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-40-2**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[[6-methoxy-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-41-3** **403808-42-4**, N-[3,5-Dichlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-43-5** **403808-46-8**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-49-1**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-50-4**, N-[4-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-51-5** **403808-52-6**, N-[2-(2,4-Dichlorophenyl)ethyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-53-7**, N-[3-Bromophenyl)methyl]-4-[2-


[(2-(2-quinolylamino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-55-9, N-(2,2-Diphenylethyl)-4-[2-[(2-[(5-nitro-2-pyridyl]amino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-56-0 403808-58-2 403808-59-3,  
 N-[(3-Iodophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridyl]amino)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-97-9, 4-[2-[(2-Phenoxyethyl)amino]pyrimidin-4-yl]benzamide  
 403809-14-3, 4-[2-[(2-[2-Pyridyl]ethyl)amino]pyrimidin-4-yl]benzamide 403809-15-4, 4-[2-[(2-Phenylpropyl)amino]pyrimidin-4-yl]benzamide 403809-16-5 403809-17-6,  
 4-[2-[(2-[(5-Cyano-2-pyridyl]amino)ethyl]amino]pyrimidin-4-yl]benzamide  
 403809-19-8, 4-[2-[(3-(4-Nitroimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-20-1, 4-[2-[(2-[(4-Amino-5-cyanopyrimidin-2-yl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-22-3,  
 4-[2-[(2-(2,5-Dimethoxyphenyl)ethyl)amino]pyrimidin-4-yl]benzamide  
 403809-23-4, 4-[2-[(2-(2,3-Dimethoxyphenyl)ethyl)amino]pyrimidin-4-yl]benzamide 403809-24-5, 4-[2-[(3-(4-Methoxyphenoxy)propyl)amino]pyrimidin-4-yl]benzamide 403809-25-6  
 , 4-[2-[(2-[(5-Nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide  
 403809-27-8, 4-[2-[(3-(4,5-Dichloroimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-28-9, 4-[2-[(2-[(5-(Aminothioxomethyl)-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-29-0  
 , 4-[2-[(3-[(5-Nitro-2-pyridyl)amino]propyl)amino]pyrimidin-4-yl]benzamide  
 403809-30-3, 4-[2-[(3-(4-Phenylimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-31-4 403809-32-5  
 403809-33-6, 4-[2-[(2-[(5-(Trifluoromethyl)-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-37-0,  
 4-[2-[(3-[3-(Trifluoromethyl)phenoxy]propyl)amino]pyrimidin-4-yl]benzamide  
 403809-51-8 403809-92-7, N-[(3-Bromophenyl)methyl]-4-[2-[(2-(pyrimidin-2-ylamino)ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403810-07-1 403810-50-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (preparation of aminopyrimidines and -pyridines as glycogen synthase kinase  
 3 inhibitors)


RN 403806-71-3 CAPLUS  
 CN Benzamide, 4-[2-[(4-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-72-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 403806-74-6 CAPLUS  
 CN Benzamide, 4-[2-[(3-methylphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-75-7 CAPLUS  
 CN Benzamide, 4-[2-[(4-aminophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-76-8 CAPLUS  
 CN Benzamide, 4-[2-[(5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-78-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-80-4 CAPLUS  
 CN Benzamide, 4-[2-[(4-cyanophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-methoxyphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-82-6 CAPLUS  
 CN Benzamide, 4-[2-[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-83-7 CAPLUS  
 CN Benzamide, 4-[2-[(2-(4-fluorophenyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-87-1 CAPLUS  
 CN Benzamide, 4-[2-[(3-chlorophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-92-8 CAPLUS  
 CN Benzamide, 4-[2-[(4-phenylbutyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS  
 CN Benzamide, 4-[2-[(2-(3-methoxyphenyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-96-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-phenoxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS  
 CN Benzamide, 4-[2-[(3-nitrophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-03-4 CAPLUS  
 CN Benzamide, 4-[2-[(1-naphthalenylmethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-10-3 CAPLUS  
 CN Benzamide, 4-[2-[(3-methylphenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-11-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-(1,3-benzodioxol-5-yl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS  
 CN Benzamide, 4-[2-[(2-(4-nitrophenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS  
 CN Benzamide, 4-[2-[(2,6-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS  
 CN Benzamide, 4-[2-[(3,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS  
 CN Benzamide, 4-[2-[[[3-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS  
 CN Benzamide, 4-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS  
 CN Benzamide, 4-[2-[[[3,5-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-23-8 CAPLUS  
 CN Benzamide, 4-[2-[[[2,4-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-27-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-(3-methoxyphenoxy)propyl]amino)-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 403807-32-9 CAPLUS  
 CN Benzamide, 4-{2-[[3-[4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]propyl]amino}-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-33-0 CAPLUS  
 CN Benzamide, 4-[2-[[3-[4-(3-methoxyphenyl)-1H-imidazol-1-yl]propyl]amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-36-3 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4-chlorophenoxy)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-37-4 CAPLUS  
 CN Benzamide, 4-[2-[(4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-38-5 CAPLUS  
 CN Benzamide, 4-[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS  
 CN Benzamide, 4-[2-[(3-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-43-2 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2-benzothiazolylamino)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-46-5 CAPLUS  
 CN Benzamide, 4-[2-[(2,2-diphenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS  
 CN Benzamide, 4-[2-[(3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS  
 CN Benzamide, 4-[2-[(3'-amino[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS  
 CN Benzamide, 4-[2-[(3'-amino[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-51-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-(6-quinolinyloxy)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-56-7 CAPLUS  
 CN Benzoic acid, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403807-57-8 CAPLUS  
 CN Benzamide, N-(phenylmethyl)-4-[2-[[2-(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS  
 CN Benzamide, 4-[2-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-62-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-(2,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-63-6 CAPLUS  
 CN Benzamide, 4-[2-[(3-(3,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-64-7 CAPLUS  
 CN Benzamide, 4-[2-[[3-([1,1'-biphenyl]-3-yloxy)propyl]amino]-4-pyrimidinyl]-  
 (9CI) (CA INDEX NAME)




RN 403807-65-8 CAPLUS  
 CN Benzamide, 4-[2-[[3'-(methylamino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-68-1 CAPLUS  
 CN Benzamide, 4-[2-[[3-(3-bromophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 403807-77-2 CAPLUS  
 CN Benzamide, N-(2-methoxyethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS  
 CN Benzamide, 4-[2-[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS  
 CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403807-83-0 CAPLUS  
 CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-90-9 CAPLUS  
 CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403807-93-2 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-94-3 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-99-8 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 403808-03-7 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-07-1 CAPLUS


CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 403808-08-2 CAPLUS

CN Benzamide, N-[(3-methylphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


- Me

RN 403808-11-7 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-12-8 CAPLUS  
 CN Benzamide, N-[(5-methylpyrazinyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Me


RN 403808-13-9 CAPLUS  
 CN Benzamide, N-[(3-fluorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-15-1 CAPLUS

CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[(3-bromophenyl)methyl]amino]-4-pyrimidinyl-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-18-4 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-19-5 CAPLUS

CN Benzamide, N-[ (3-bromophenyl)methyl]-4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-21-9 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 403808-22-0 CAPLUS

CN Benzamide, N-[ (4-methoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-26-4 CAPLUS

CN Benzamide, N-[ (3-chlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


- Cl

RN 403808-27-5 CAPLUS  
 CN Benzamide, N-[(3,4-difluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-30-0 CAPLUS  
 CN Benzamide, N-[(3-nitrophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


- NO<sub>2</sub>

RN 403808-32-2 CAPLUS  
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-33-3 CAPLUS

CN Benzamide, N-(1-naphthalenylmethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-37-7 CAPLUS

CN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

—OMe


RN 403808-38-8 CAPLUS

CN Benzamide, N-[(2,3-dimethoxyphenyl)methyl]-4-[2-[[2-[(5-nitro-2-

Page 131

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

→ OMe

RN 403808-40-2 CAPLUS


CN Benzamide, N-[ (3-bromophenyl)methyl]-4-[2-[2-[ (6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-41-3 CAPLUS

CN Benzamide, 4-[2-[2-[ (5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[ (3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


→ CF<sub>3</sub>

RN 403808-42-4 CAPLUS

CN Benzamide, N-[ (3,5-dichlorophenyl)methyl]-4-[2-[2-[ (5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

\_Cl

RN 403808-43-5 CAPIUS

CN Benzamide, N-[{3,4-dichlorophenyl}methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

\_Cl

RN 403808-46-8 CAPIUS


CN Benzamide, N-[{(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-48-0 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Br

RN 403808-49-1 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Br

RN 403808-50-4 CAPLUS

CN Benzamide, N-[(4-bromophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


- Br

RN 403808-51-5 CAPLUS  
 CN Benzamide, N-[{4-(aminosulfonyl)phenyl]methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 403808-52-6 CAPLUS  
 CN Benzamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 403808-53-7 CAPLUS  
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


-Br

RN 403808-55-9 CAPLUS  
 CN Benzamide, N-(2,2-diphenylethyl)-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-56-0 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(3-bromophenyl)methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Br

RN 403808-58-2 CAPLUS  
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(5-(trifluoromethyl)-2-pyridinyl]amino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

- Br


RN 403808-59-3 CAPLUS  
 CN Benzamide, N-[(3-iodophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-97-9 CAPLUS  
 CN Benzamide, 4-[2-[(2-phenoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-14-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-pyridinyl)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 403809-15-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-phenylpropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403809-16-5 CAPLUS  
 CN Benzamide, 4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403809-17-6 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-19-8 CAPLUS

CN Benzamide, 4-[2-[[3-(4-nitro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-20-1 CAPLUS


CN Benzamide, 4-[2-[[2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2,5-dimethoxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2,3-dimethoxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-24-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4-methoxyphenoxy)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-25-6 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-27-8 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4,5-dichloro-1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403809-28-9 CAPLUS  
 CN Benzamide, 4-[2-[[2-[[5-(aminothioxomethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-29-0 CAPLUS  
 CN Benzamide, 4-[2-[[3-[(5-nitro-2-pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-30-3 CAPLUS  
 CN Benzamide, 4-[2-[[3-(4-phenyl-1H-imidazol-1-yl)propyl]amino]-4-

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-31-4 CAPLUS

CN Benzamide, 4-[2-[(3-(1-naphthalenyl)propyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)


RN 403809-32-5 CAPLUS

CN Benzamide, 4-[2-[(3-(5,6-dimethyl-1H-benzimidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-33-6 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-(trifluoromethyl)-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-37-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-[3-(trifluoromethyl)phenoxy]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-51-8 CAPLUS  
 CN Benzamide, 4-[2-[(3-(5,6-dichloro-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403809-92-7 CAPLUS  
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403810-07-1 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[(2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




L8 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:449662 CAPLUS  
 DN 137:33310  
 TI Preparation of anilinopyrimidines as IKK inhibitors  
 IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;  
 Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
 PA Signal Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 194 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046171	A2	20020613	WO 2001-US46403	20011205
	WO 2002046171	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003203926	A1	20031030	US 2001-4642	20011204
	CA 2431160	AA	20020613	CA 2001-2431160	20011205
	AU 2002020195	A5	20020618	AU 2002-20195	20011205
	EP 1349841	A2	20031008	EP 2001-999564	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004523497	T2	20040805	JP 2002-547910	20011205
PRAI	US 2000-251816P	P	20001206		
	WO 2001-US46403	W	20011205		
OS	MARPAT 137:33310				
AB	The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 1 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.				
IT	434945-24-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of anilinopyrimidines as IKK inhibitors)				
RN	434945-24-1 CAPLUS				
CN	Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				



IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of anilinopyrimidines as IKK inhibitors)

RN 434950-55-7 CAPLUS

CN Benzoic acid, 4-[2-[(4-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]-, ethyl  
ester (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:449661 CAPLUS  
 DN 137:33309  
 TI Preparation of anilinopyrimidines as JNK pathway inhibitors  
 IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;  
 Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.  
 PA Signal Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 199 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430966	AA	20020613	CA 2001-2430966	20011205
	AU 2002027214	A5	20020618	AU 2002-27214	20011205
	EP 1349840	A2	20031008	EP 2001-996103	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534728	T2	20041118	JP 2002-547909	20011205
PRAI	US 2000-251904P	P	20001206		
	WO 2001-US46402	W	20011205		

OS MARPAT 137:33309

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of  $\leq$  10  $\mu$ M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.


IT 434945-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of anilinopyrimidines as JNK pathway inhibitors)

RN 434945-24-1 CAPLUS

CN Benzoic acid, 4-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




IT 434950-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of anilinopyrimidines as JNK pathway inhibitors)

RN 434950-55-7 CAPLUS

CN Benzoic acid, 4-[2-[(4-(aminocarbonyl)phenyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:185092 CAPLUS  
 DN 136:247598  
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors  
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 268 pp.  
 CODEN: PIIXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020495	A2	20020314	WO 2001-US42081	20010906
	WO 2002020495	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, EI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095026	A5	20020322	AU 2001-95026	20010906
	EP 1317433	A2	20030611	EP 2001-975734	20010906
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004514656	T2	20040520	JP 2002-525117	20010906
PRAI	US 2000-230480P	P	20000906		
	WO 2001-US42081	W	20010906		
OS	MARPAT 136:247598				
AB	Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO <sub>2</sub> , (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free assay with IC <sub>50</sub> values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar				

IT disorder, immunodeficiency, or cancer (no data).


IT 252904-09-9P, Benzamide, N-[{(3-bromophenyl)methyl]-4-[2-[(3-[(5-nitro-2-pyridinyl)amino]propyl)amino]-4-pyrimidinyl]- 252904-11-3P , Benzamide, N-[{(3-bromophenyl)methyl]-4-[2-[(2-[(5-cyano-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- 252904-13-5P, Benzamide, N-[{(3-methoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- 252904-31-7P, Benzamide, 4-[2-[(2-(2-pyridinylamino)ethyl)amino]-4-pyrimidinyl]- 252904-32-8P, Benzamide, 4-[2-[(2-(2-quinolinylamino)ethyl)amino]-4-pyrimidinyl]- 252904-33-9P, Benzamide, 4-[2-[(2-(6-methoxy-2-pyridinyl)amino)ethyl)amino]-4-pyrimidinyl]- 252904-34-0P, Benzamide, 4-[2-[(3-(1H-benzimidazol-1-yl)propyl)amino]-4-pyrimidinyl]- 252904-35-1P, Benzamide, 4-[2-[(3-(2-naphthalenyloxy)propyl)amino]-4-pyrimidinyl]- 252904-36-2P, Benzenepropanamide,  $\alpha$ -[[4-[2-[(2-(2-pyridinyl)ethyl)amino]-4-pyrimidinyl]benzoyl]amino]-, ( $\alpha$ S)-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)


RN 252904-09-9 CAPLUS

CN Benzamide, N-[{(3-bromophenyl)methyl]-4-[2-[(3-[(5-nitro-2-pyridinyl)amino]propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-11-3 CAPLUS


CN Benzamide, N-[{(3-bromophenyl)methyl]-4-[2-[(2-[(5-cyano-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS

CN Benzamide, N-[{(3-methoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—OMe


RN 252904-31-7 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2-pyridinylamino)ethyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 252904-32-8 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2-quinolinylamino)ethyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 252904-33-9 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-methoxy-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-34-0 CAPLUS

CN Benzamide, 4-[2-[(3-(1H-benzimidazol-1-yl)propyl)amino]-4-pyrimidinyl]-  
(9CI) (CA INDEX NAME)

RN 252904-35-1 CAPLUS

CN Benzamide, 4-[2-[(3-(2-naphthalenoxy)propyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

RN 252904-36-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[4-[2-[(2-pyridinyl)ethyl]amino]-4-pyrimidinyl]benzoyl]amino-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)**Absolute stereochemistry.**IT 403806-71-3, 4-[2-[(4-Pyridylmethyl)amino]pyrimidin-4-yl]benzamide  
403806-72-4 403806-74-6, 4-[2-[(3-

Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-75-7**,  
 4-[2-[(4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403806-76-8**, 4-[2-[(5-Methylpyrazin-2-yl)methyl]amino]pyrimidin-4-  
 yl]benzamide **403806-78-0**, 4-[2-[(3-Imidazolylpropyl)amino]pyrimi-  
 din-4-yl]benzamide **403806-80-4**, 4-[2-[(4-  
 Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-81-5**,  
 4-[2-[(3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403806-82-6**, 4-[2-[(4-Methoxyphenyl)methyl]amino]pyrimidin-4-  
 yl]benzamide **403806-83-7**, 4-[2-[(2-(4-  
 Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403806-87-1**,  
 4-[2-[(3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403806-92-8**, 4-[2-[(4-Phenylbutyl)amino]pyrimidin-4-yl]benzamide  
**403806-94-0**, 4-[2-[(2-(3-Methoxyphenyl)ethyl)amino]pyrimidin-4-  
 yl]benzamide **403806-96-2**, 4-[2-[(3-Phenoxypropyl)amino]pyrimidin-  
 4-yl]benzamide **403806-98-4**, 4-[2-[(3-  
 Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-02-3**,  
 4-[2-[(2-(3-Chlorophenyl)ethyl)amino]pyrimidin-4-yl]benzamide  
**403807-03-4**, 4-[2-[(Naphthylmethyl)amino]pyrimidin-4-yl]benzamide  
**403807-10-3**, 4-[2-[(3-(3-Methylphenoxy)propyl)amino]pyrimidin-4-  
 yl]benzamide **403807-11-4**, 4-[2-[(2-(2H-Benzo[3,4-d]-1,3-dioxolan-  
 5-yl)ethyl)amino]pyrimidin-4-yl]benzamide **403807-12-5**,  
 4-[2-[(2-(4-Nitrophenyl)ethyl)amino]pyrimidin-4-yl]benzamide  
**403807-13-6**, 4-[2-[(2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-  
 yl]benzamide **403807-14-7**, 4-[2-[(3,4-  
 Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-19-2**  
 , 4-[2-[(3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-20-5**, 4-[2-[(4-(Trifluoromethyl)phenyl)methyl]amino]pyrimi-  
 din-4-yl]benzamide **403807-21-6**, 4-[2-[(3,5-  
 Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-23-8**  
 , 4-[2-[(2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-27-2**, 4-[2-[(3-(3-Methoxyphenoxy)propyl)amino]pyrimidin-4-  
 yl]benzamide **403807-32-9**, 4-[2-[(3-[4-(2,4-  
 Dichlorophenyl)imidazolyl]propyl)amino]pyrimidin-4-yl]benzamide  
**403807-33-0**, 4-[2-[(3-[4-(3-Methoxyphenyl)imidazolyl]propyl)amino]  
 pyrimidin-4-yl]benzamide **403807-36-3**, 4-[2-[(3-[4-  
 Chlorophenoxy)propyl)amino]pyrimidin-4-yl]benzamide **403807-37-4**,  
 4-[2-[(4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-38-5**, 4-[2-[(4-(4-Fluorophenyl)phenyl)methyl]amino]pyrimid-  
 in-4-yl]benzamide **403807-39-6**, 4-[2-[(3-  
 Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-43-2**,  
 4-[2-[(2-(Benzothiazol-2-ylamino)ethyl)amino]pyrimidin-4-yl]benzamide  
**403807-46-5**, 4-[2-[(2,2-Diphenylethyl)amino]pyrimidin-4-  
 yl]benzamide **403807-47-6**, 4-[2-[(3,4,5-  
 Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-49-8**  
 , 4-[2-[(3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-50-1**, 4-[2-[(4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidi-  
 n-4-yl]benzamide **403807-51-2**, 4-[2-[(3-(6-  
 Quinolyl)oxy)propyl]amino]pyrimidin-4-yl]benzamide **403807-56-7**,  
 Ethyl 4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-  
 yl]benzoate **403807-57-8**, N-Benzyl-4-[2-[(2-[2-  
 pyridyl)ethyl)amino]pyrimidin-4-yl]phenylcarboxamide **403807-60-3**  
 , 4-[2-[(3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide  
**403807-62-5**, 4-[2-[(3-(2,4-Dichlorophenoxy)propyl)amino]pyrimidin-  
 4-yl]benzamide **403807-63-6**, 4-[2-[(3-(3,4-  
 Dichlorophenoxy)propyl)amino]pyrimidin-4-yl]benzamide **403807-64-7**  
 , 4-[2-[(3-(3-Phenylphenoxy)propyl)amino]pyrimidin-4-yl]benzamide  
**403807-65-8**, 4-[2-[(3-[3-(Methylamino)methyl]phenyl)phenyl]methy-  
 l]amino]pyrimidin-4-yl]benzamide **403807-68-1**,

4-[2-[[3-(3-Bromophenoxy)propyl]amino]pyrimidin-4-yl]benzamide  
**403807-77-2**, N-(2-Methoxyethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403807-78-3**, 4-[2-[[3-[3-(Acetylamino)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-79-4**, 4-[2-[[3,5-Bis(trifluoromethyl)phenyl]methyl]amino]pyrimidin-4-yl]benzamide  
**403807-83-0**, 4-[2-[[3-[3-(Trifluoromethyl)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-90-9**, N-(Oxolan-2-ylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403807-93-2**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide  
**403807-94-3**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(3-pyridylmethyl)carboxamide **403807-99-8**, N-(2-Thienylmethyl)-4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-03-7**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(4-piperidylmethyl)carboxamide **403808-07-1**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylethyl)carboxamide **403808-08-2**, N-[3-Methylphenyl)methyl]-4-[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-11-7**, [4-[2-[[2-[[6-Amino-5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-benzylcarboxamide  
**403808-12-8**, N-[5-Methylpyrazin-2-yl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-13-9**, N-[3-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-15-1**, N-[4-Fluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-16-2**, [4-[2-[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]phenyl-N-[3-methylphenyl)methyl]carboxamide **403808-18-4**, N-(3-Imidazolylpropyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-19-5** **403808-21-9**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenyl]-N-(2-phenylcyclopropyl)carboxamide **403808-22-0**, N-[4-Methoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-26-4**, N-[3-Chlorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-27-5**, N-[3,4-Difluorophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-30-0**, [4-[2-[[2-[[5-Nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-32-2**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[[3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-33-3**, N-(Naphthylmethyl)-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-37-7**, N-[3,4-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-38-8**, N-[2,3-Dimethoxyphenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-40-2**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[[6-methoxy-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-41-3** **403808-42-4**, N-[3,5-Dichlorophenyl)methyl]-4-[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-43-5** **403808-46-8**  
**403808-48-0**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[(4-nitrophenyl)amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide  
**403808-49-1**, N-[3-Bromophenyl)methyl]-4-[2-[[2-[[5-nitro-2-pyridyl]amino]ethyl]amino]pyrimidin-4-yl]phenylcarboxamide


403808-50-4, N-[(4-Bromophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-51-5 403808-52-6, N-[2-(2,4-Dichlorophenyl)ethyl]-4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]phenylcarboxamide 403808-53-7, N-[(3-Bromophenyl)methyl]-4-[2-[(2-(2-quinolylamino)ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-55-9, N-(2,2-Diphenylethyl)-4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-56-0 403808-58-2 403808-59-3,  
 N-[(3-Iodophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403808-97-9, 4-[2-[(2-Phenoxyethyl)amino]pyrimidin-4-yl]benzamide  
 403809-14-3, 4-[2-[(2-Pyridyl)ethyl]amino]pyrimidin-4-yl]benzamide 403809-15-4, 4-[2-[(2-Phenylpropyl)amino]pyrimidin-4-yl]benzamide 403809-16-5 403809-17-6,  
 4-[2-[(2-[(5-Cyano-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide  
 403809-19-8, 4-[2-[(3-(4-Nitroimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-20-1, 4-[2-[(2-[(4-Amino-5-cyanopyrimidin-2-yl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-22-3,  
 4-[2-[(2-(2,5-Dimethoxyphenyl)ethyl)amino]pyrimidin-4-yl]benzamide 403809-23-4, 4-[2-[(2-(2,3-Dimethoxyphenyl)ethyl)amino]pyrimidin-4-yl]benzamide 403809-24-5, 4-[2-[[3-(4-Methoxyphenoxy)propyl]amino]pyrimidin-4-yl]benzamide 403809-25-6  
 , 4-[2-[(2-[(5-Nitro-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide  
 403809-27-8, 4-[2-[(3-(4,5-Dichloroimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-28-9, 4-[2-[(2-[(5-(Aminothioxomethyl)-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-29-0  
 , 4-[2-[[3-[(5-Nitro-2-pyridyl)amino]propyl]amino]pyrimidin-4-yl]benzamide 403809-30-3, 4-[2-[(3-(4-Phenylimidazolyl)propyl)amino]pyrimidin-4-yl]benzamide 403809-31-4 403809-32-5  
 403809-33-6, 4-[2-[(2-[(5-(Trifluoromethyl)-2-pyridyl)amino]ethyl)amino]pyrimidin-4-yl]benzamide 403809-37-0,  
 4-[2-[(3-(Trifluoromethyl)phenoxy)propyl]amino]pyrimidin-4-yl]benzamide  
 403809-51-8 403809-92-7, N-[(3-Bromophenyl)methyl]-4-[2-[(2-(pyrimidin-2-ylamino)ethyl)amino]pyrimidin-4-yl]phenylcarboxamide  
 403810-07-1 403810-50-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 403806-71-3 CAPLUS


CN Benzamide, 4-[2-[(4-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-72-4 CAPLUS

CN Benzamide, 4-[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)


RN 403806-74-6 CAPLUS

CN Benzamide, 4-[2-[(3-methylphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA  
INDEX NAME)

RN 403806-75-7 CAPLUS


CN Benzamide, 4-[2-[(4-aminophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA  
INDEX NAME)

RN 403806-76-8 CAPLUS


CN Benzamide, 4-[2-[(5-methylpyrazinyl)methyl]amino]-4-pyrimidinyl- (9CI)  
(CA INDEX NAME)

RN 403806-78-0 CAPLUS


CN Benzamide, 4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




RN 403806-80-4 CAPLUS  
 CN Benzamide, 4-[2-[(4-cyanophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-methoxyphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-82-6 CAPLUS  
 CN Benzamide, 4-[2-[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-83-7 CAPLUS  
 CN Benzamide, 4-[2-[(2-(4-fluorophenyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-87-1 CAPLUS  
 CN Benzamide, 4-[2-[(3-chlorophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-92-8 CAPLUS  
 CN Benzamide, 4-[2-[(4-phenylbutyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS  
 CN Benzamide, 4-[2-[(2-(3-methoxyphenyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-96-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-phenoxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS  
 CN Benzamide, 4-[2-[(3-nitrophenyl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-(3-chlorophenyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-03-4 CAPLUS  
 CN Benzamide, 4-[2-[(1-naphthalenylmethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-10-3 CAPLUS  
 CN Benzamide, 4-[2-[(3-methylphenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-11-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-(1,3-benzodioxol-5-yl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS  
 CN Benzamide, 4-[2-[(2-(4-nitrophenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS  
 CN Benzamide, 4-[2-[(2,6-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS  
 CN Benzamide, 4-[2-[(3,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS  
 CN Benzamide, 4-[2-[[[3-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS  
 CN Benzamide, 4-[2-[[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS  
 CN Benzamide, 4-[2-[[[3,5-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-23-8 CAPLUS  
 CN Benzamide, 4-[2-[[[(2,4-dichlorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-27-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-methoxyphenoxy)propyl]amino]-4-pyrimidinyl- (9CI)  
 (CA INDEX NAME)



RN 403807-32-9 CAPLUS  
 CN Benzamide, 4-[2-[[3-[4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-33-0 CAPLUS  
 CN Benzamide, 4-[2-[[3-[4-(3-methoxyphenyl)-1H-imidazol-1-yl]propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-36-3 CAPLUS

CN Benzamide, 4-[2-[(3-(4-chlorophenoxy)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-37-4 CAPLUS

CN Benzamide, 4-[2-[(4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-38-5 CAPLUS

CN Benzamide, 4-[2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS


CN Benzamide, 4-[2-[(3-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-43-2 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2-benzothiazolylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-46-5 CAPLUS  
 CN Benzamide, 4-[2-[(2,2-diphenylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS  
 CN Benzamide, 4-[2-[(3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS  
 CN Benzamide, 4-[2-[(3'-amino[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS  
 CN Benzamide, 4-[2-[(3'-amino[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-51-2 CAPLUS  
 CN Benzamide, 4-[2-[(3-(6-quinolinyloxy)propyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-56-7 CAPLUS  
 CN Benzoic acid, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403807-57-8 CAPLUS  
 CN Benzamide, N-(phenylmethyl)-4-[2-[(2-(2-pyridinyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS  
 CN Benzamide, 4-[2-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 403807-62-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-(2,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-63-6 CAPLUS  
 CN Benzamide, 4-[2-[(3-(3,4-dichlorophenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403807-64-7 CAPLUS

CN Benzamide, 4-[2-[[3-([1,1'-biphenyl]-3-yloxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-65-8 CAPLUS

CN Benzamide, 4-[2-[[3'-(methylamino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-68-1 CAPLUS

CN Benzamide, 4-[2-[[3-(3-bromophenoxy)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-77-2 CAPLUS

CN Benzamide, N-(2-methoxyethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS


CN Benzamide, 4-[2-[[3'-(acetylamino)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS  
 CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403807-83-0 CAPLUS  
 CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-90-9 CAPLUS  
 CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 403807-93-2 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-94-3 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403807-99-8 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 403808-03-7 CAPLUS

CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-07-1 CAPLUS


CN Benzamide, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 403808-08-2 CAPLUS

CN Benzamide, N-[(3-methylphenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


- Me

RN 403808-11-7 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 403808-12-8 CAPLUS  
 CN Benzamide, N-[(5-methylpyrazinyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Me


RN 403808-13-9 CAPLUS  
 CN Benzamide, N-[(3-fluorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-15-1 CAPLUS

CN Benzamide, N-[(4-fluorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[(3-bromophenyl)methyl]amino]-4-pyrimidinyl-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-18-4 CAPLUS

CN Benzamide, N-[(3-(1H-imidazol-1-yl)propyl)-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-19-5 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-21-9 CAPLUS


CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]-N-(2-phenylcyclopropyl)- (9CI) (CA INDEX NAME)



RN 403808-22-0 CAPLUS

CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-26-4 CAPLUS

CN Benzamide, N-[(3-chlorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Cl

RN 403808-27-5 CAPLUS


CN Benzamide, N-[(3,4-difluorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-30-0 CAPLUS

CN Benzamide, N-[(3-nitrophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-NO<sub>2</sub>


RN 403808-32-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-33-3 CAPLUS


CN Benzamide, N-(1-naphthalenylmethyl)-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-37-7 CAPLUS

CN Benzamide, N-[(3,4-dimethoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—OMe

RN 403808-38-8 CAPLUS

CN Benzamide, N-[(2,3-dimethoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 403808-40-2 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(6-methoxy-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-41-3 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CF<sub>3</sub>


RN 403808-42-4 CAPLUS

CN Benzamide, N-[(3,5-dichlorophenyl)methyl]-4-[2-[(2-[(5-nitro-2-

Page 176

pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 403808-43-5 CAPLUS

CN Benzamide, N-[(3,4-dichlorophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 403808-46-8 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-48-0 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(4-nitrophenyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Br

RN 403808-49-1 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

- Br

RN 403808-50-4 CAPLUS

CN Benzamide, N-[(4-bromophenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

-Br


RN 403808-51-5 CAPLUS

CN Benzamide, N-[{4-(aminosulfonyl)phenyl]methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 403808-52-6 CAPLUS

CN Benzamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 403808-53-7 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


- Br

RN 403808-55-9 CAPLUS  
 CN Benzamide, N-(2,2-diphenylethyl)-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403808-56-0 CAPLUS  
 CN Benzamide, 4-[2-[[2-[(6-amino-5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br

RN 403808-58-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Br


RN 403808-59-3 CAPLUS

CN Benzamide, N-[(3-iodophenyl)methyl]-4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-97-9 CAPLUS


CN Benzamide, 4-[2-[(2-phenoxyethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-14-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-pyridinyl)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 403809-15-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-phenylpropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403809-16-5 CAPLUS  
 CN Benzamide, 4-[2-[[2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403809-17-6 CAPLUS

CN Benzamide, 4-[2-[(2-[(5-cyano-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-19-8 CAPLUS

CN Benzamide, 4-[2-[(3-(4-nitro-1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-20-1 CAPLUS


CN Benzamide, 4-[2-[(2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2,5-dimethoxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS  
 CN Benzamide, 4-[2-[(2-(2,3-dimethoxyphenyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-24-5 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4-methoxyphenoxy)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-25-6 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-27-8 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4,5-dichloro-1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403809-28-9 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(5-(aminothioxomethyl)-2-pyridinyl]amino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-29-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-[(5-nitro-2-pyridinyl)amino]propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-30-3 CAPLUS  
 CN Benzamide, 4-[2-[(3-(4-phenyl-1H-imidazol-1-yl)propyl)amino]-4-


**pyrimidinyl]- (9CI) (CA INDEX NAME)**




RN 403809-31-4 CAPLUS  
 CN Benzamide, 4-[2-[[3-(1-naphthalenyl)propyl]amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 403809-32-5 CAPLUS  
 CN Benzamide, 4-[2-[[3-(5,6-dimethyl-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-33-6 CAPLUS  
 CN Benzamide, 4-[2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-37-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-(trifluoromethyl)phenoxy)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403809-51-8 CAPLUS  
 CN Benzamide, 4-[2-[(3-(5,6-dichloro-1H-benzimidazol-1-yl)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 403809-92-7 CAPLUS  
 CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-(2-pyrimidinylamino)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 403810-07-1 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(4-amino-5-cyano-2-pyrimidinyl)amino]ethyl]amino]-4-pyrimidinyl-N-[(3-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[(2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)




L8 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:798080 CAPLUS  
 DN 135:339258  
 TI Medicinal compositions promoting bowel movement  
 IN Yasuda, Masahiro; Harada, Hitoshi; Miyazawa, Shuhei; Kobayashi, Seiichi;  
 Harada, Kokichi; Hida, Takayuki; Shibata, Hisashi; Yasuda, Nobuyuki;  
 Asano, Osamu; Kotake, Yoshihiko  
 PA Eisai Co., Ltd., Japan  
 SO PCT Int. Appl., 86 pp.  
 CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080893	A1	20011101	WO 2001-JP3643	20010426
	W: AU, CA, CN, HU, IL, JP, KR, MX, NO, NZ, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, TR				
	AU 2001052606	A5	20011107	AU 2001-52606	20010426
	CA 2407013	AA	20021022	CA 2001-2407013	20010426
	EP 1283056	A1	20030212	EP 2001-925974	20010426
	EP 1283056	B1	20041215		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI, CY, TR				
	AT 284712	E	20050115	AT 2001-925974	20010426
	NZ 521633	A	20050128	NZ 2001-521633	20010426
	EP 1510222	A2	20050302	EP 2004-24423	20010426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI, CY, TR				
	ZA 2002007744	A	20030926	ZA 2002-7744	20020926
	US 2003171383	A1	20030911	US 2002-257091	20021009
	NO 2002005116	A	20021223	NO 2002-5116	20021024
PRAI	JP 2000-126489	A	20000426		
	JP 2000-220124	A	20000721		
	EP 2001-925974	A3	20010426		
	WO 2001-JP3643	W	20010426		
OS	MARPAT 135:339258				
AB	Drugs having a gentle and potent effect of promoting the bowel movement without causing diarrhea. Namely, bowel movement promoters which contain compds. having an adenosine A2 receptor antagonism (preferably compds. having an adenosine A2b receptor antagonism) or salts thereof.				
IT	371230-87-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(medicinal compns. containing adenosine A2 and A2b receptor antagonists for promoting bowel movement)				
RN	371230-87-4 CAPLUS				
CN	Benzoic acid, 3-[2-amino-5-(4-pyridinyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)				



X

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2000:911230 CAPLUS  
 DN 134:71598  
 TI Preparation of 2-arylaminino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase.  
 IN Batchelor, Mark James; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 PA Celltech Chiroscience Limited, UK  
 SO PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078731	A1	20001228	WO 2000-GB2382	20000619
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US	6579983	B1	20030617	US 2000-596952	20000616
CA	2375182	AA	20001228	CA 2000-2375182	20000619
BR	2000011770	A	20020305	BR 2000-11770	20000619
EP	1187816	A1	20020320	EP 2000-940569	20000619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE	10084704	T	20020529	DE 2000-10084704	20000619
GB	2369360	A1	20020529	GB 2001-30563	20000619
JP	2003502406	T2	20030121	JP 2001-504897	20000619
ES	2188429	A1	20030616	ES 2001-50085	20000619
ES	2188429	B2	20050616		
AU	778533	B2	20041209	AU 2000-55488	20000619
BG	106116	A	20020731	BG 2001-106116	20011119
ZA	2001009841	A	20020429	ZA 2001-9841	20011129
NO	2001006162	A	20020218	NO 2001-6162	20011217
US	2002147339	A1	20021010	US 2002-151518	20020520
HK	1048815	A1	20050429	HK 2003-101022	20030212
US	2004180914	A1	20040916	US 2004-812293	20040329
PRAI	GB 1999-14258	A	19990618		
	US 2000-596952	A1	20000616		
	WO 2000-GB2382	W	20000619		
	US 2002-151518	B1	20020520		
OS	MARPAT 134:71598				
AB	Title compds. [I; Ar = (substituted) aryl, heteroaryl; R1 = H, alkyl; R2 = X1R3; X1 = bond, linker atom or group; R3 = (substituted) aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group] and the salts, solvates, hydrates and N-oxides thereof, were prepared. Thus, 3,4,5-trimethoxyphenylguanidinium nitrate (preparation given), 1-phenyl-2-cyano-3-dimethylaminopropen-1-one, and NaOH were refluxed in EtOH to give 5-cyano-4-phenyl-N-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine. I inhibited KDR kinase and FGFr kinase with IC <sub>50</sub> ≤ 1 μM.				
IT	314267-39-5P 314267-72-6P 314267-74-8P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological				

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2-arylaminino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)


RN 314267-39-5 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[(4-[2-(1H-imidazol-1-yl)ethyl]phenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 314267-72-6 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[(4-(2-hydroxyethyl)phenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 314267-74-8 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 314267-75-9p

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 2-arylaminino-5-cyanopyrimidines as inhibitors of KDR kinase and/or FGFr kinase)

RN 314267-75-9 CAPLUS

CN Benzoic acid, 4-[5-cyano-2-[(4-[2-[(4-methylphenyl)sulfonyloxy]ethyl]phenyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)

10/639,784

nyl)amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2000:457028 CAPLUS  
 DN 133:89545  
 TI Substituted (aminoiminomethyl- or aminomethyl)benzoheteroaryl compounds useful as anticoagulants  
 IN Dankulich, William P.; McGarry, Daniel G.; Burns, Christopher; Gallagher, Timothy F.; Volz, Francis A.  
 PA Aventis Pharmaceuticals Products Inc., USA  
 SO PCT Int. Appl., 215 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039087	A2	20000706	WO 1999-US30623	19991222
	WO 2000039087	A3	20001109		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2358047	AA	20000706	CA 1999-2358047	19991222
	EP 1140901	A2	20011010	EP 1999-966560	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916845	A	20011030	BR 1999-16845	19991222
	JP 2002533438	T2	20021008	JP 2000-590999	19991222
	EE 200100341	A	20021216	EE 2001-341	19991222
	AU 760983	B2	20030529	AU 2000-22071	19991222
	NZ 512548	A	20030829	NZ 1999-512548	19991222
	US 6541505	B1	20030401	US 2000-609103	20000630
	NO 2001003142	A	20010821	NO 2001-3142	20010622
	US 2003153604	A1	20030814	US 2003-372499	20030224
PRAI	US 1998-113710P	A2	19981224		
	WO 1999-US30623	W	19991222		
	US 2000-609103	A1	20000630		

OS MARPAT 133:89545

AB The invention is directed to (aminoiminomethyl)- or (aminomethyl)- substituted benzoheteroaryl compds. I, which are useful as inhibitors of Factor Xa (no data) [wherein X = O, S, NH or derivs.; L1 = alkylene, alkenylene, alkynylene; L2 = bond, or as given for L1; Q = NH or derivs., O, CO, COO, OCO, NHCO or derivs., S(O)0-2, SO2NH or derivs, etc.; R = H, cycloalkyl, heterocyclyl, aryl, wide range of other cyclic groups; R2, R3 = H; or R2R3 = NH or derivs.]. The invention is also directed to compns. containing the compds., methods for their preparation, and their use, e.g., in

the


inhibition of thrombin formation, or for treating a patient suffering from, or subject to, a disease state associated with excess thrombin. Approx. 160 examples were prepared and claimed, and hundreds of intermediates were prepared. For instance, 4-(pyrid-3-yl)benzoic acid underwent amidation with 3-cyano-5-(2-aminoethyl)indole using TBTU and DIEA, and the product nitrile was treated with HCl(g) in MeOH followed by NH3 in MeOH, to give the invention compound II.

IT 291232-31-3P, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-

(dimethylamino)ethyl]amino]pyrimidin-4-yl]benzamide **281232-40-4P**  
, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[2-(morpholin-4-  
yl)ethylamino]pyrimidin-4-yl]benzamide **281232-41-5P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-(dimethylamino)propyl)amino]py-  
rimidin-4-yl]benzamide **281233-85-0P**, 4-[2-[(2-  
(Dimethylamino)ethyl]amino]pyrimidin-4-yl]benzoic acid  
**281233-86-1P**, 4-[2-[(2-(Dimethylamino)ethyl]amino]pyrimidin-4-  
yl]benzoic acid trifluoroacetic acid salt **281234-04-6P**,  
4-[2-[(2-(Morpholin-4-yl)ethyl]amino]pyrimidin-4-yl]benzoic acid  
**281234-05-7P**, 4-[2-[(3-(Dimethylamino)propyl)amino]pyrimidin-4-  
yl]benzoic acid **281234-07-9P**, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-  
4-[2-[(2-hydroxy-1-(hydroxymethyl)ethyl]amino]pyrimidin-4-yl]benzamide  
**281234-08-0P**, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(5-  
(dimethylamino)pentyl)amino]pyrimidin-4-yl]benzamide **281234-09-1P**  
, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-morpholin-4-  
ylpentylamino)pyrimidin-4-yl]benzamide **281234-10-4P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-piperidin-1-  
ylpentylamino)pyrimidin-4-yl]benzamide **281234-11-5P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(5-pyrrolidin-1-  
ylpentylamino)pyrimidin-4-yl]benzamide **281234-18-2P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(6-pyrrolidin-1-  
ylhexylamino)pyrimidin-4-yl]benzamide **281234-19-3P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(6-piperidin-1-  
ylhexylamino)pyrimidin-4-yl]benzamide **281234-20-6P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(4-piperidin-1-  
ylbutylamino)pyrimidin-4-yl]benzamide **281234-21-7P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(4-(diethylamino)butyl)amino]pyri-  
midin-4-yl]benzamide **281234-22-8P**, N-[2-(3-Cyano-1H-indol-5-  
yl)ethyl]-4-[2-(6-morpholin-4-ylhexylamino)pyrimidin-4-yl]benzamide  
**281234-23-9P**, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(6-  
(dimethylamino)hexyl)amino]pyrimidin-4-yl]benzamide **281234-24-0P**  
, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(4-  
(dimethylamino)butyl)amino]pyrimidin-4-yl]benzamide **281234-25-1P**  
, 4-[2-[(Bicyclo[2.2.1]hept-2-yl)amino]pyrimidin-4-yl]-N-[2-(3-cyano-1H-  
indol-5-yl)ethyl]benzamide **281234-31-9P**, N-[2-(3-Cyano-1H-indol-  
5-yl)ethyl]-4-[2-(3-hydroxypropylamino)pyrimidin-4-yl]benzamide  
**281234-36-4P**, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(2,3-  
dihydroxypropylamino)pyrimidin-4-yl]benzamide **281234-40-0P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-(2-oxoimidazolidin-1-  
yl)ethyl)amino]pyrimidin-4-yl]benzamide **281234-41-1P**,  
N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-[2-(3-methoxypropylamino)pyrimidin-4-  
yl]benzamide **281234-42-2P**, N-[2-(3-Cyano-1H-indol-5-yl)ethyl]-4-  
[2-(2-hydroxyethylamino)pyrimidin-4-yl]benzamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(intermediate; preparation of substituted (aminoiminomethyl- or  
aminomethyl)benzoheteroaryl compds. as anticoagulants)


RN 281232-31-3 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-  
(dimethylamino)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281232-40-4 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281232-41-5 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-(dimethylamino)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281233-85-0 CAPLUS

CN Benzoic acid, 4-[2-[(2-(dimethylamino)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281233-86-1 CAPLUS

CN Benzoic acid, 4-[2-[(2-(dimethylamino)ethyl)amino]-4-pyrimidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 281233-85-0


CMF C15 H18 N4 O2




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 281234-04-6 CAPLUS  
 CN Benzoic acid, 4-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)




RN 281234-05-7 CAPLUS  
 CN Benzoic acid, 4-[2-[(3-(dimethylamino)propyl)amino]-4-pyrimidinyl]- (9CI)  
 (CA INDEX NAME)



RN 281234-07-9 CAPLUS  
 CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-hydroxy-1-(hydroxymethyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-08-0 CAPLUS  
 CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(5-(dimethylamino)pentyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-09-1 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(4-morpholinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-10-4 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(1-piperidinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-11-5 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[5-(1-pyrrolidinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-18-2 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(1-pyrrolidinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-19-3 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[[6-(1-

**piperidinyl)hexyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)**


RN 281234-20-6 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(4-(1-piperidinyl)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-21-7 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(4-(diethylamino)butyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-22-8 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(6-(4-morpholinyl)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-23-9 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(6-(dimethylamino)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281234-24-0 CAPIUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(4-dimethylamino)butyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281234-25-1 CAPIUS

CN Benzamide, 4-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-pyrimidinyl]-N-[2-(3-cyano-1H-indol-5-yl)ethyl- (9CI) (CA INDEX NAME)




RN 281234-31-9 CAPIUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281234-36-4 CAPIUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2,3-dihydroxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281234-40-0 CAPIUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-(2-oxo-1-imidazolidinyl)ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281234-41-1 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(3-methoxypropyl)amino]pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281234-42-2 CAPLUS

CN Benzamide, N-[2-(3-cyano-1H-indol-5-yl)ethyl]-4-[2-[(2-hydroxyethyl)amino]pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 281230-73-7P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-dimethylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281230-82-8P,  
, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(2-morpholin-4-ylethylamino)pyrimidin-4-yl]benzamide 281230-83-9P,  
N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(3-dimethylamino)propyl]amino]pyrimidin-4-yl]benzamide 281230-88-4P  
, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-hydroxymethyl)ethyl]amino]pyrimidin-4-yl]benzamide 281230-89-5P  
, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-(imidazol-1-yl)propylamino)pyrimidin-4-yl]benzamide 281230-91-9P,  
N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-diisopropylamino)ethyl]amino]pyrimidin-4-yl]benzamide  
281230-92-0P, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-dibutylamino)ethyl]amino]pyrimidin-4-yl]benzamide 281230-93-1P,  
N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]benzamide 281230-94-2P,  
N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(3-diethylamino)propyl]amino]pyrimidin-4-yl]benzamide 281230-95-3P  
, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-piperidin-1-ylpropylamino)pyrimidin-4-yl]benzamide 281230-97-5P,  
N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(5-(dimethylamino)pentyl)amino]pyrimidin-4-yl]benzamide 281230-98-6P  
, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-morpholin-4-ylpentylamino)pyrimidin-4-yl]benzamide 281230-99-7P,

N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-piperidin-1-ylpentylamino)pyrimidin-4-yl]benzamide **281231-00-3P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(5-pyrrolidin-1-ylpentylamino)pyrimidin-4-yl]benzamide **281231-18-3P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-pyrrolidin-1-ylhexylamino)pyrimidin-4-yl]benzamide **281231-19-4P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-piperidin-1-ylhexylamino)pyrimidin-4-yl]benzamide **281231-20-7P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(4-piperidin-1-ylbutylamino)pyrimidin-4-yl]benzamide **281231-21-8P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(4-diethylamino)butyl]amino]pyrimidin-4-yl]benzamide **281231-22-9P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(6-morpholin-4-ylhexylamino)pyrimidin-4-yl]benzamide **281231-23-0P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(6-dimethylamino)hexyl]amino]pyrimidin-4-yl]benzamide **281231-24-1P**,  
 N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(4-dimethylaminobutyl)amino]pyrimidin-4-yl]benzamide **281231-25-2P**,  
 4-[2-[(Bicyclo[2.2.1]hept-2-yl)amino]pyrimidin-4-yl]-N-[2-(3-carbamimidoyl-1H-indol-5-yl)ethyl]benzamide **281231-31-0P**, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-hydroxypropylamino)pyrimidin-4-yl]benzamide **281231-36-5P**, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-(2,3-dihydroxypropylamino)pyrimidin-4-yl)benzamide **281231-40-1P**, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-(2-oxoimidazolidin-1-yl)ethyl)amino]pyrimidin-4-yl]benzamide **281231-41-2P**, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-(3-methoxypropylamino)pyrimidin-4-yl]benzamide **281231-42-3P**, N-[2-(3-Carbamimidoyl-1H-indol-5-yl)ethyl]-4-[2-[(2-hydroxyethyl)amino]pyrimidin-4-yl]benzamide **281235-35-6P** **281235-42-5P** **281235-43-6P** **281235-44-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (target compound; preparation of substituted (aminoiminomethyl- or aminomethyl)benzoheteroaryl compds. as anticoagulants)

RN **281230-73-7 CAPLUS**


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-(dimethylamino)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN **281230-82-8 CAPLUS**

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-(4-morpholinyl)ethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>


RN 281230-83-9 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(3-dimethylamino)propyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281230-88-4 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-hydroxymethyl)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 281230-89-5 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 281230-91-9 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-[(bis(1-methylethyl)amino)ethyl]amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>

RN 281230-92-0 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-[(dibutylamino)ethyl]amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH<sub>2</sub>


RN 281230-93-1 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(4-morpholinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-94-2 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(diethylamino)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-95-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[3-(1-piperidinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-97-5 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(dimethylamino)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 281230-98-6 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[[5-(4-

morpholinyl)pentyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281230-99-7 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(5-(1-piperidinyl)pentyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-00-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(5-(1-pyrrolidinyl)pentyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-18-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(6-(1-pyrrolidinyl)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-19-4 CAPLUS


CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(6-(1-piperidinyl)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-20-7 CAPLUS  
 CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(4-(1-piperidinyl)butyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-21-8 CAPLUS  
 CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(4-(diethylamino)butyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-22-9 CAPLUS  
 CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(6-(4-morpholinyl)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-23-0 CAPLUS  
 CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(6-(dimethylamino)hexyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 281231-24-1 CAPLUS  
 CN Benzamide, N-[2-{3-(aminoiminomethyl)-1H-indol-5-yl}ethyl]-4-[2-[(4-dimethylamino)butyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281231-25-2 CAPLUS  
 CN Benzamide, N-[2-{3-(aminoiminomethyl)-1H-indol-5-yl}ethyl]-4-[2-[(bicyclo[2.2.1]hept-2-yl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 281231-31-0 CAPLUS  
 CN Benzamide, N-[2-{3-(aminoiminomethyl)-1H-indol-5-yl}ethyl]-4-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281231-36-5 CAPLUS  
 CN Benzamide, N-[2-{3-(aminoiminomethyl)-1H-indol-5-yl}ethyl]-4-[2-[(2,3-dihydroxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 281231-40-1 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-oxo-1-imidazolidinyl)ethyl]amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)

## PAGE 1-A




## PAGE 1-B

—NH<sub>2</sub>


RN 281231-41-2 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(3-methoxypropyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 281231-42-3 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-hydroxyethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 281235-35-6 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(2-(dimethylamino)ethyl)amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 281230-73-7


CMF C26 H30 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 281235-42-5 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(6-(dimethylamino)hexyl)amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 281231-23-0

CMF C30 H38 N8 O




CM 2


CRN 76-05-1  
CMF C<sub>2</sub> H F<sub>3</sub> O<sub>2</sub>

RN 281235-43-6 CAPLUS  
 CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-[(4-(dimethylamino)butyl)amino]-4-pyrimidinyl]-, tris(trifluoroacetate) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 281231-24-1  
CMF C<sub>28</sub> H<sub>34</sub> N<sub>8</sub> O

CM 2

CRN 76-05-1  
CMF C<sub>2</sub> H F<sub>3</sub> O<sub>2</sub>


RN 281235-44-7 CAPLUS

CN Benzamide, N-[2-[3-(aminoiminomethyl)-1H-indol-5-yl]ethyl]-4-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-pyrimidinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 281231-25-2


CMF C29 H31 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



L8 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:811233 CAPLUS  
 DN 132:64265  
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors  
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithry; Renhowe, Paul A.; Seely, Lynn; Subramanian, Sharadha; Wagman, Allan S.; Zhou, Xiaohui A.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 262 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9965897	A1	19991223	WO 1999-US13809	19990618
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949566	A1	20000105	AU 1999-49566	19990618
	EP 1087963	A1	20010404	EP 1999-933522	19990618
	EP 1087963	B1	20040825		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6489344	B1	20021203	US 1999-336098	19990618
	JP 2003527303	T2	20030916	JP 2000-554722	19990618
	AT 274510	E	20040915	AT 1999-933522	19990618
	US 2003130289	A1	20030710	US 2002-309535	20021203
PRAI	US 1998-89978P	P	19980619		
	US 1999-336098	A3	19990618		
	WO 1999-US13809	W	19990618		
OS	MARPAT 132:64265				
AB	RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared. Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.				
IT	252904-09-9P 252904-11-3P 252904-13-5P 252904-31-7P 252904-32-8P 252904-33-9P 252904-34-0P 252904-35-1P 252904-36-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)				
RN	252904-09-9 CAPLUS				
CN	Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[3-[(5-nitro-2-				

pyridinyl)amino]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-11-3 CAPLUS


CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[(2-[(5-cyano-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 252904-13-5 CAPLUS

CN Benzamide, N-[(3-methoxyphenyl)methyl]-4-[2-[(2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—OMe

RN 252904-31-7 CAPLUS


CN Benzamide, 4-[2-[(2-(2-pyridinylamino)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 252904-32-8 CAPLUS  
 CN Benzamide, 4-[2-[(2-quinolinylamino)ethyl]amino]-4-pyrimidinyl- (9CI)  
 (CA INDEX NAME)




RN 252904-33-9 CAPLUS  
 CN Benzamide, 4-[2-[(2-[(6-methoxy-2-pyridinyl)amino]ethyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 252904-34-0 CAPLUS  
 CN Benzamide, 4-[2-[(3-(1H-benzimidazol-1-yl)propyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 252904-35-1 CAPLUS

CN Benzamide, 4-[2-[[3-(2-naphthalenyl)propyl]amino]-4-pyrimidinyl]- (9CI)  
(CA INDEX NAME)

RN 252904-36-2 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[(4-[(2-[(2-pyridinyl)ethyl]amino)-4-pyrimidinyl]benzoyl)amino]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999:723017 CAPLUS  
 DN 131:337034  
 TI Preparation of 1-naphthylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors  
 IN Nowak, Thorsten; Preston, John; Rayner, John Wall; Smithers, Michael James; Stocker, Andrew  
 PA Zeneca Limited, UK  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9957099	A1	19991111	WO 1999-GB1312	19990427
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
AU 9936207	A1	19991123	AU 1999-36207	19990427
EP 1082303	A1	20010314	EP 1999-918179	19990427
EP 1082303	B1	20050126		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
AT 287874	E	20050215	AT 1999-918179	19990427
US 6395731	B1	20020528	US 2000-674563	20001220
PRAI GB 1998-9349	A	19980502		
WO 1999-GB1312	W	19990427		
OS MARPAT 131:337034				
AB Title compds. (I) [where A = 5- or 6-membered monocyclic heteroaryl (un)substituted by 1-3 halo, oxo, CO <sub>2</sub> H, CF <sub>3</sub> , CN, NH <sub>2</sub> , OH, NO <sub>2</sub> , (amino)alkyl, alkoxy(carbonyl), and/or (di)alkylamino; Y = (un)substituted phenylene; Z = (un)substituted piperidine-4,1-diyl or piperazine-1,4-diyl; D and D <sub>1</sub> = independently H, alkyl, alkenyl, alkynyl, oxo, or OH; E = F, Cl, or Br] were prepared as antithrombotics and anticoagulants. Thus, 4-(4-imidazolyl)benzoic acid HCl (2-step preparation given) was amidated with 1-(6-chloronaphth-2-ylsulfonyl)piperazine to yield the title imidazolylbenzoylpiperazine (II). The IC <sub>50</sub> values of invention compds. ranged from 0.001 to 0.1 μM for Factor Xa inhibition and were > 40 μM for thrombin inhibition (no individual data given). Data for anticoagulant activity of I in conventional prothrombin time tests were given.				
IT 249887-66-9P 249887-68-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(target compound; preparation of 1-naphthylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors for treatment of thrombosis mediated diseases and coagulation disorders)			
RN 249887-66-9 CAPLUS				
CN Piperazine, 1-[{(6-chloro-2-naphthalenyl)sulfonyl}-4-[4-{2-[(2-dimethylamino)ethyl]amino}-4-pyrimidinyl]benzoyl]- (9CI) (CA INDEX NAME)				



RN 249887-68-1 CAPLUS  
CN Glycine, N-[4-[4-[(4-chloro-2-naphthalenyl)sulfonyl]-1-piperazinyl]carbonylphenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1998:794998 CAPLUS  
 DN 130:38404  
 TI Preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related compounds as inhibitors of activated coagulation factor X.  
 IN Tawada, Hiroyuki; Ito, Fumio; Moriya, Norihiko; Terashita, Zenichi  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 313 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9854164	A1	19981203	WO 1998-JP2346	19980528
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2287292	AA	19981203	CA 1998-2287292	19980528
	AU 9874534	A1	19981230	AU 1998-74534	19980528
	EP 986551	A1	20000322	EP 1998-921852	19980528
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11236372	A2	19990831	JP 1998-148677	19980529
	US 6359134	B1	20020319	US 1999-424892	19991130
PRAI	JP 1997-142250	A	19970530		
	JP 1997-351806	A	19971219		
	WO 1998-JP2346	W	19980528		
OS	MARPAT 130:38404				
AB	R1SO2ACOYXZ [R1 = (substituted) hydrocarbyl, heterocyclyl; A = (substituted) divalent N-heterocyclyl; Y = (substituted) hydrocarbylene, heterocyclylene; X = bond, (substituted) alkylene; Z = substituted amino, imidoyl, N-heterocyclyl; provided that when X = bond and Z = (substituted) 6-membered N-heterocyclyl, then Y = (substituted) hydrocarbylene, unsatd. heterocyclylene], were prepared. Thus, reaction of 1-(6-chloronaphthalene-2-sulfonyl)piperazine hydrochloride with 2-(4-pyridyl)-4-methyl-5-thiazolecarboxylic acid in the presence of Et3N and WSC hydrochloride in DMF gave 1-(6-chloronaphthalene-2-sulfonyl)-4-[2-(4-pyridyl)-4-methyl-5-thiazolecarbonyl]piperazine. The latter inhibited human activated coagulation factor X with IC50 = 0.019 μM.				
IT	216958-01-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related compds. as inhibitors of activated coagulation factor X)				
RN	216958-01-9 CAPLUS				
CN	Piperazine, 1-[4-(2-amino-4-pyrimidinyl)benzoyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)				




IT 216959-98-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 1-benzoyl-4-naphthalenesulfonylpiperazines and related  
 compds. as inhibitors of activated coagulation factor X)

RN 216959-98-7 CAPLUS

CN Benzoic acid, 4-(2-amino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1997:457074 CAPLUS  
 DN 127:81461  
 TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors  
 IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719065	A1	19970529	WO 1996-GB2854	19961120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958935	A	19990928	US 1996-753041	19961119
	AU 9676314	A1	19970611	AU 1996-76314	19961120
	EP 862560	A1	19980909	EP 1996-939171	19961120
	EP 862560	B1	20030402		
	R: CH, DE, ES, FR, GB, IT, LI				
	ES 2195020	T3	20031201	ES 1996-939171	19961120
	US 6235746	B1	20010522	US 1999-249760	19990216
PRAI	GB 1995-23675	A	19951120		
	US 1996-753041	A3	19961119		
	WO 1996-GB2854	W	19961120		
OS	MARPAT 127:81461				
AB	The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom. group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared. Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4·H2O in EtOH afforded I·2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.				
IT	191727-37-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors)				
RN	191727-37-4 CAPLUS				

CN Benzoic acid, 4-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1995:909361 CAPLUS  
 DN 123:313996  
 TI Preparation of N-phenyl-2-pyrimidineamine antitumor agents  
 IN Zimmermann, Juerg  
 PA Ciba-Geigy A.-G., Switz.  
 SO PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
**FAN.CNT 1**


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509847	A1	19950413	WO 1994-EP3150	19940921
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2148931	AA	19950413	CA 1993-2148931	19930921
	AU 9476976	A1	19950501	AU 1994-76976	19940921
	AU 693475	B2	19980702		
	EP 672035	A1	19950920	EP 1994-927634	19940921
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08503971	T2	19960430	JP 1994-510577	19940921
	US 5612340	A	19970318	US 1995-436345	19950517
PRAI	CH 1993-2967	A	19931001		
	CH 1994-2279	A	19940718		
	WO 1994-EP3150	W	19940921		
OS	MARPAT 123:313996				
AB	N-phenyl-2-pyrimidineamine derivs. [I; R1 = naphthyl, fluorenyl, anthracenyl, (un)substituted cyclic residue, etc.; R2 = NO <sub>2</sub> , F-substituted lower alkoxy, etc.] [e.g., N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine; m.p. 132°], useful for the treatment of tumor diseases (no data), are prepared and I-containing formulations presented.				
IT	170141-39-6P 170141-40-9P 170141-41-0P 170141-42-1P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-phenyl-2-pyrimidineamine antitumor agents)				
RN	170141-39-6 CAPLUS				
CN	Benzamide, 3-[2-[(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				




RN 170141-40-9 CAPLUS  
 CN Benzamide, N-(2-aminoethyl)-3-[2-[(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 170141-41-0 CAPLUS  
 CN Benzamide, N-(2-hydroxyethyl)-3-[2-[(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 170141-42-1 CAPLUS  
 CN Benzoic acid, 3-[2-[(3-(1,1,2,2-tetrafluoroethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1984:34487 CAPLUS  
 DN 100:34487  
 TI 2-Benzazepines. 7. Synthesis of pyrimido[5,4-d][2]benzazepines  
 AU Earley, James V.; Fryer, R. Ian; Gilman, Norman W.  
 CS Dep. Chem., Hoffmann-La Roche Inc., Nutley, NJ, 07110, USA  
 SO Journal of Heterocyclic Chemistry (1983), 20(5), 1195-7  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 100:34487  
 AB Two novel syntheses of pyrimido[5,4-d][2]benzazepine I are described. The first synthesis started with 3-phenylphthalide which in 3 steps was converted to a functionalized pyrimidine II which was cyclized to give I. The second approach used o-benzoylbenzoic acid Me ester as the starting material, which in 4 steps was converted to II.  
 IT 76988-36-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
     (preparation and reductive cyclization of, pyrimidobenzazepine from)  
 RN 76988-36-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)


X




L8 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1981:139827 CAPLUS  
 DN 94:139827  
 TI Benzazepine derivatives, intermediates for their preparation, their use  
     and pharmaceutical compositions containing them  
 IN Fryer, Rodney Ian; Gilman, Norman W.; Trybulski, Eugene J.; Walser, Armin  
 PA Hoffmann-La Roche, F., und Co. A.-G., Switz.  
 SO Eur. Pat. Appl., 92 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA German  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 14470	A2	19800820	EP 1980-100610	19800206
	EP 14470	A3	19820210		
	EP 14470	B1	19850710		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	AT 13420	E	19850615	AT 1982-100359	19800204
	DK 8000498	A	19800808	DK 1980-498	19800205
	NL 8000715	A	19800811	NL 1980-715	19800205
	FR 2450833	A1	19801003	FR 1980-2469	19800205
	FR 2450833	B1	19830610		
	CA 1138863	A1	19830104	CA 1980-345062	19800205
	IL 59316	A1	19830731	IL 1980-59316	19800205
	SU 1181547	A3	19850923	SU 1980-2879255	19800205
	FI 8000367	A	19800808	FI 1980-367	19800206
	FI 68832	B	19850731		
	FI 68832	C	19851111		
	NO 8000316	A	19800808	NO 1980-316	19800206
	NO 153138	B	19851014		
	NO 153138	C	19860122		
	SE 8000964	A	19800808	SE 1980-964	19800206
	AU 8055296	A1	19800814	AU 1980-55296	19800206
	AU 535233	B2	19840308		
	DE 3004381	A1	19800904	DE 1980-3004381	19800206
	JP 55122782	A2	19800920	JP 1980-12578	19800206
	JP 59007715	B4	19840220		
	GB 2043636	A	19801008	GB 1980-3910	19800206
	GB 2043636	B2	19830511		
	BR 8000737	A	19801021	BR 1980-737	19800206
	ES 488311	A1	19801216	ES 1980-488311	19800206
	DD 149066	C	19810624	DD 1980-218921	19800206
	IN 151574	A	19830528	IN 1980-CA138	19800206
	HU 25090	O	19830530	HU 1980-271	19800206
	HU 182662	B	19840228		
	AT 14225	E	19850715	AT 1980-100610	19800206
	CS 241471	B2	19860313	CS 1980-799	19800206
	RO 79168	P	19820625	RO 1980-100118	19800207
	PL 125349	B1	19830430	PL 1980-230173	19800207
	ES 495078	A1	19810701	ES 1980-495078	19800916
	ES 495077	A1	19811001	ES 1980-495077	19800916
	ES 495079	A1	19811001	ES 1980-495079	19800916
	ES 495080	A1	19811016	ES 1980-495080	19800916
	US 4481142	A	19841106	US 1982-437047	19821027
	US 4546183	A	19851008	US 1984-643509	19840823
	US 4547581	A	19851015	US 1984-643563	19840823
	PRAI US 1979-10118	A	19790207		

US 1979-16709 A 19790301  
 CH 1980-510 A 19800122  
 CH 1980-511 A 19800122  
 EP 1982-100359 A 19800204  
 EP 1980-100610 A 19800206  
 US 1980-151025 A1 19800519  
 US 1982-437047 A3 19821027  
 OS CASREACT 94:139827  
 AB Pyrimido[5,4-d][2]benzazepines I [R = H, R1 = H or alkyl, or RR1 = bond; R2 = H, Br, Cl, OH, SH, alkoxy, alkylthio, (alkylated) amino, or CH<sub>2</sub>COR<sub>6</sub>, where R<sub>6</sub> = H, alkoxy, or (alkylated) amino; R3 = H, NH<sub>2</sub> or dialkylamino; R4 = H, OH or acyloxy; R5 = H, halo, CF<sub>3</sub>, Et, HOCHMe, or MeCO; X = H or halo; m, n = 0 or 1, the latter only when RR1 = bond], which showed sedative activity in tests on cats and mice, were prepared. Thus, cyclocondensation of 8-chloro-1-(2-chlorophenyl)-3,4-dihydro-4-[ (dimethylamino)methylene]-5H-2-benzazepin-2-one with MeC(:NH)NH<sub>2</sub>.HCl gave I (RR1 = bond, R2 = Me, R3 = R4 = H, R5 = X = Cl, m = n = 0).  
 IT 76988-32-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
     (preparation and hydrogenation of)  
 RN 76988-32-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-[4-chloro-2-(2-fluorobenzoyl)phenyl]-(9CI) (CA INDEX NAME)




IT 76988-36-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
     (preparation and hydrogenation-cyclocondensation of)  
 RN 76988-36-8 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-benzoylphenyl)-(9CI) (CA INDEX NAME)





L8 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1974:70833 CAPLUS  
 DN 80:70833  
 TI 2,4-Bis(o-carboxyanilino)pyrimidines or their salts  
 IN Fadeicheva, A. G.; Karp, V. K.; Portnyagina, V. A.; Trinus, F. P.;  
 Mokhort, N. A.; Faktorovich, I. L.; Barkova, I. S.  
 PA Kiev Scientific-Research Institute of Pharmacology and Toxicology  
 SO U.S.S.R.  
 From: Otkrytiya, Izobret., Prom. Obraztsy, Tovarnye Znaki 1973, 50(36),  
 44.  
 CODEN: URXXAF  
 DT Patent  
 LA Russian  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 396334	T	19730829	SU 1971-1681393	19710708
PRAI	SU 1971-1681393	A	19710708		
AB	The pyrimidines I (R = H, alkyl, halo, CO <sub>2</sub> H; R <sub>1</sub> = H, alkyl, halo, NO <sub>2</sub> ) were prepared by the reaction of the corresponding 2,4-dichloropyrimidine with o-H <sub>2</sub> NC <sub>6</sub> H <sub>4</sub> CO <sub>2</sub> H in an organic solvent, e.g., DMF or AcOH, at 100-10°.				
IT	51126-66-0DP, Benzoic acid, 2-[2-[(2-carboxyphenyl)amino]-4-pyrimidinyl]-, derivative RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	51126-66-0 CAPLUS				
CN	Benzoic acid, 2-[2-[(2-carboxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				



L8 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1962:74764 CAPLUS  
 DN 56:74764  
 OREF 56:14588b-c  
 TI Radiation prophylaxis by some new purines and pyrimidines  
 AU Krasnykh, I. G.; Shashkov, V. S.; Magidson, O. Yu.; Golovchinskaya, E. S.; Chkhikvadze, K. A.  
 SO Farmakologiya i Toksikologiya (Moscow) (1961), 24, 572-7  
 CODEN: FATOAO; ISSN: 0014-8318  
 DT Journal  
 LA Unavailable  
 AB Mice were given intraperitoneal or subcutaneous injections, 10-15 min. prior to exposure to 700 r. (x-rays), of 4 uracils, 3 caffeine derivs., a theobromine derivative, and 12 pyrimidines. Up to 20% protection against radiation damage was given by compds. containing aminoethyl or aminomethyl groups, as against 50-60% protection with mercamine. Some compds. caused hypothermia, in no apparent relation to protective effect. Some drugs were given as the free base, others as hydrohalides. Doses and results are tabulated.  
 IT 95770-36-8, Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester, hydrochloride  
     (in radiation-damage prevention)  
 RN 95770-36-8 CAPLUS  
 CN Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI)  
     (CA INDEX NAME)



● HCl

=> => d his

(FILE 'HOME' ENTERED AT 19:41:04 ON 11 DEC 2005)

FILE 'REGISTRY' ENTERED AT 19:41:11 ON 11 DEC 2005

L1 STRUCTURE uploaded  
L2 50 S L1 SSS SAM  
L3 STRUCTURE uploaded  
L4 50 S L3 SSS SAM  
L5 STRUCTURE uploaded  
L6 27 S L5 SSS SAM  
L7 446 S LS SSS FUL

FILE 'CAPLUS' ENTERED AT 19:45:07 ON 11 DEC 2005



L8 29 S L7

FILE 'CAOLD' ENTERED AT 19:46:16 ON 11 DEC 2005

=> s 17  
L9 1 L7

=> d 19 bib,hitstr

L9 ANSWER 1 OF 1 CAOLD COPYRIGHT 2005 ACS on STN  
AN CA56:14588b CAOLD  
TI radiation prophylaxis by purines and pyrimidines  
AU Krasnykh, I. G.; Shashkov, V. S.; Magidson, O. Yu.; Golovchinskaya, E. S.; Chkhikvadze, K. A.  
IT 95770-36-8  
RN 95770-36-8 CAOLD  
CN Benzoic acid, o-(2-amino-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI)  
(CA INDEX NAME)



● HCl

10/639,784

=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.26	311.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-21.17

STN INTERNATIONAL LOGOFF AT 19:46:38 ON 11 DEC 2005



Application Number

IDS Flag Clearance for Application



Content	Mailroom Date	Entry Number	IDS Review	Reviewer
M844	04-06-2004	16	<input checked="" type="checkbox"/>	08-11-2005 00:50:32 IDS CONV